WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, March 22, 2005

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L15	L14 AND abeta	48
☐	L14	(lewy bodies OR alpha-synuclein)	1563
☐	L13	L12 AND abeta	16
☐	L12	L9 AND alpha-synuclein	23
☐	L11	L10 AND abeta	1
☐	L10	L9 AND lewy bodies	22
☐	L9	424/130.1,141.1,142.1,178.1,179.1,185.1,193.1.CCLS.	5414
☐	L8	MASLIAH.IN.	33
☐	L7	MASLIAH-E.IN.	11
☐	L6	MASLIAH-ELIEZER.IN.	11
☐	L5	Schenk.IN.	3043
☐	L4	Schenk-D.IN.	11
☐	L3	Schenk-D-B.IN.	19
☐	L2	Schenk-Dale.IN.	3
☐	L1	(Schenk-Dale-B.IN.)	68

END OF SEARCH HISTORY

5849988
6710226
6743427
6750324
6761888
6787138
6787139
6787140
6787143
6787637
6803379
6808712
6818218
6825229
6866849
6866850
US20020187157
US20030086938
US20030157117
US20030171356
US20040013680
US20040072261
US20040091945
US20040265919

WO2004047854A

NCBI PubMed National Library of Medicine NLM [Sign In]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journal

Search PubMed for Lewy Body AND abeta Go Clear Sav

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

All: 32 Review: 6

Text Version

Items 1 - 32 of 32 One p

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: van Horssen J, de Vos RA, Steur EN, David G, Wesseling P, de Waal RM, Verbeek MM. Related Articles, l

Absence of heparan sulfate proteoglycans in Lewy bodie and Lewy neurites in Parkinson's disease brains.
J Alzheimers Dis. 2004 Oct;6(5):469-74.
PMID: 15505367 [PubMed - indexed for MEDLINE]

2: Windisch M, Hutter-Paier B, Schreiner E, Wronski R. Related Articles, l

Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?
J Mol Neurosci. 2004;24(1):155-65.
PMID: 15314265 [PubMed - indexed for MEDLINE]

3: Hamilton RL, Bowser R. Related Articles, l

Alzheimer disease pathology in amyotrophic lateral sclerosis.
Acta Neuropathol (Berl). 2004 Jun;107(6):515-22. Epub 2004 M 16.
PMID: 15024584 [PubMed - indexed for MEDLINE]

4: Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, Jensen PH. Related Articles, l

Proteasomal inhibition by alpha-synuclein filaments and oligomers.
J Biol Chem. 2004 Mar 26;279(13):12924-34. Epub 2004 Jan 7.
PMID: 14711827 [PubMed - indexed for MEDLINE]

5: Related Articles, l

Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW

Jr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ.

Cerebrospinal fluid tau and beta-amyloid: how well do tl biomarkers reflect autopsy-confirmed dementia diagnose
Arch Neurol. 2003 Dec;60(12):1696-702.
PMID: 14676043 [PubMed - indexed for MEDLINE]

☐ **6:** Hashimoto M, Masliah E. Related Articles, l

Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Le\ bodies.
Neurochem Res. 2003 Nov;28(11):1743-56. Review.
PMID: 14584828 [PubMed - indexed for MEDLINE]

☐ **7:** Masliah E, Alford M, Adame A, Rockenstein E, Galasko D, Salmon D, Hansen LA, Thal LJ. Related Articles, l

Abeta1-42 promotes cholinergic sprouting in patients wi AD and Lewy body variant of AD.
Neurology. 2003 Jul 22;61(2):206-11.
PMID: 12874400 [PubMed - indexed for MEDLINE]

☐ **8:** Hashimoto M, Rockenstein E, Masliah E. Related Articles, l

Transgenic models of alpha-synuclein pathology: past, present, and future.
Ann N Y Acad Sci. 2003 Jun;991:171-88. Review.
PMID: 12846986 [PubMed - indexed for MEDLINE]

☐ **9:** Wirths O, Bayer TA. Related Articles, l

Alpha-synuclein, Abeta and Alzheimer's disease.
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):1C Review.
PMID: 12551731 [PubMed - indexed for MEDLINE]

☐ **10:** Terada S, Ishizu H, Yokota O, Tsuchiya K, Nakashima H, Ishihara T, Fujita D, Ueda K, Ikeda K, Kuroda S. Related Articles, l

Glial involvement in diffuse Lewy body disease.
Acta Neuropathol (Berl). 2003 Feb;105(2):163-9. Epub 2002 O 25.
PMID: 12536227 [PubMed - indexed for MEDLINE]

☐ **11:** Xu G, Gonzales V, Borchelt DR. Related Articles, l

Rapid detection of protein aggregates in the brains of Alzheimer patients and transgenic mouse models of amyloidosis.
Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):191-5.
PMID: 12218651 [PubMed - indexed for MEDLINE]

☐ **12:** Xia Y, Saitoh T, Ueda K, Tanaka S, Chen X, Hashimoto M, Hsu L, Conrad C, Sundsmo M, Yoshimoto M, Thal L, Katzman R, Masliah E. Related Articles, l

Characterization of the human alpha-synuclein gene: Genomic structure, transcription start site, promoter reg and polymorphisms.
J Alzheimers Dis. 2001 Oct;3(5):485-494.
PMID: 12214035 [PubMed - as supplied by publisher]

☐ **13:** Yokota O, Terada S, Ishizu H, Tsuchiya K, Kitamura Y, Ikeda K, Ueda K, Kuroda S. Related Articles, l

NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC).
Acta Neuropathol (Berl). 2002 Oct;104(4):333-41. Epub 2002 M 8.
PMID: 12200618 [PubMed - indexed for MEDLINE]

☐ **14:** Kotzbauer PT, Trojanowsk JQ, Lee VM. Related Articles, l

Lewy body pathology in Alzheimer's disease.
J Mol Neurosci. 2001 Oct;17(2):225-32. Review.
PMID: 11816795 [PubMed - indexed for MEDLINE]

☐ **15:** Leroy K, Duyckaerts C, Bovekamp L, Muller O, Anderton BH, Brion JP. Related Articles, l

Increase of adenomatous polyposis coli immunoreactivi is a marker of reactive astrocytes in Alzheimer's disease and in other pathological conditions.
Acta Neuropathol (Berl). 2001 Jul;102(1):1-10.
PMID: 11547943 [PubMed - indexed for MEDLINE]

☐ **16:** Ferrer I. Related Articles, l

[Alpha-synucleinopathies]
Neurologia. 2001 Apr;16(4):163-70. Review. Spanish.
PMID: 11412709 [PubMed - indexed for MEDLINE]

☐ **17:** Montine TJ, Kaye JA, Montine KS, Related Articles, l

McFarland L, Morrow JD, Quinn JF.

Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls.
Arch Pathol Lab Med. 2001 Apr;125(4):510-2.
PMID: 11260625 [PubMed - indexed for MEDLINE]

☐ **18:** Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E. Related Articles, I

Standardization of measurement of beta-amyloid(1-42) cerebrospinal fluid and plasma.
Amyloid. 2000 Dec;7(4):245-58.
PMID: 11132093 [PubMed - indexed for MEDLINE]

☐ **19:** Duda JE, Lee VM, Trojanowski JQ. Related Articles, I

Neuropathology of synuclein aggregates.
J Neurosci Res. 2000 Jul 15;61(2):121-7. Review.
PMID: 10878583 [PubMed - indexed for MEDLINE]

☐ **20:** Armstrong RA, Cairns NJ, Lantos PL. Related Articles, I

Beta-amyloid deposition in the temporal lobe of patient with dementia with Lewy bodies: comparison with non-demented cases and Alzheimer's disease.
Dement Geriatr Cogn Disord. 2000 Jul-Aug;11(4):187-92.
PMID: 10867443 [PubMed - indexed for MEDLINE]

☐ **21:** Campbell BC, Li QX, Culvenor JG, Jakala P, Cappai R, Beyreuther K, Masters CL, McLean CA. Related Articles, I

Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies.
Neurobiol Dis. 2000 Jun;7(3):192-200.
PMID: 10860784 [PubMed - indexed for MEDLINE]

☐ **22:** Conway KA, Harper JD, Lansbury PT Jr. Related Articles, I

Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Biochemistry. 2000 Mar 14;39(10):2552-63.
PMID: 10704204 [PubMed - indexed for MEDLINE]

☐ **23:** Wakabayashi K, Yoshimoto M, Fukushima T, Koide R, Horikawa Y, Morita T, Takahashi H. Related Articles, I

Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adu onset Hallervorden-Spatz disease with Lewy bodies.
Neuropathol Appl Neurobiol. 1999 Oct;25(5):363-8.
PMID: 10564525 [PubMed - indexed for MEDLINE]

☐ **24:** Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Ueda K, Ikeda K, Kawai M. Related Articles, I

Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in spor Parkinson's disease and in dementia with Lewy bodies.
Brain Res. 1999 Oct 2;843(1-2):53-61.
PMID: 10528110 [PubMed - indexed for MEDLINE]

☐ **25:** Culvenor JG, McLean CA, Cutt S, Campbell BC, Maher F, Jakala P, Hartmann T, Beyreuther K, Masters CL, Li QX. Related Articles, I

Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.
Am J Pathol. 1999 Oct;155(4):1173-81.
PMID: 10514400 [PubMed - indexed for MEDLINE]

☐ **26:** Lippa CF, Ozawa K, Mann DM, Ishii K, Smith TW, Arawaka S, Mori H. Related Articles, I

Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheir disease.
Arch Neurol. 1999 Sep;56(9):1111-8.
PMID: 10488812 [PubMed - indexed for MEDLINE]

☐ **27:** Bayer TA, Jakala P, Hartmann T, Havas L, McLean C, Culvenor JG, Li QX, Masters CL, Falkai P, Beyreuther K. Related Articles, I

Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but in Alzheimer's disease beta-amyloid plaque cores.
Neurosci Lett. 1999 May 14;266(3):213-6.
PMID: 10465711 [PubMed - indexed for MEDLINE]

☐ **28:** Arai T, Akiyama H, Ikeda K, Kondo H, Mori H. Related Articles, l

Immunohistochemical localization of amyloid beta-prot with amino-terminal aspartate in the cerebral cortex of patients with Alzheimer's disease.
Brain Res. 1999 Mar 27;823(1-2):202-6.
PMID: 10095028 [PubMed - indexed for MEDLINE]

☐ **29:** Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H. Related Articles, l

Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy.
Acta Neuropathol (Berl). 1998 Nov;96(5):445-52.
PMID: 9829807 [PubMed - indexed for MEDLINE]

☐ **30:** Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Sisk A, Masliah E. Related Articles, l

Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein Lewy body disease as revealed by proteinase K and for acid pretreatment.
Lab Invest. 1998 Sep;78(9):1169-77.
PMID: 9759660 [PubMed - indexed for MEDLINE]

☐ **31:** Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H. Related Articles, l

NACP, a presynaptic protein, immunoreactivity in Lew bodies in Parkinson's disease.
Neurosci Lett. 1997 Dec 12;239(1):45-8.
PMID: 9547168 [PubMed - indexed for MEDLINE]

☐ **32:** Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E. Related Articles, l

Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders.
Am J Pathol. 1998 Feb;152(2):367-72.
PMID: 9466562 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Write to the Help Desk

1: Am J Pathol. 1998 Feb;152(2):367-72. Related Articles,

Abnormal accumulation of NACP/alpha-synucle in neurodegenerative disorders.

Takeda A, Mallory M, Sundsmo M, Honer W, Hansen Masliah E.

Department of Neurosciences, University of California, S Diego, School of Medicine La Jolla, 92093-0624, USA.

The precursor of the non-Abeta component of Alzheimer' disease amyloid (NACP) (also known as a-synuclein) is a presynaptic terminal molecule that accumulates in the pla of Alzheimer's disease. Recent studies have shown that a mutation in NACP is associated with familial Parkinson's disease, and that Lewy bodies are immunoreactive with antibodies against this molecule. To clarify the patterns o accumulation and differences in abnormal compartmentalization, we studied NACP immunoreactivi using double immunolabeling and laser scanning confoca microscopy in the cortex of patients with various neurodegenerative disorders. In Lewy body variant of Alzheimer's disease, diffuse Lewy body disease, and Parkinson's disease, NACP was found to immunolabel cortical Lewy bodies, abnormal neurites, and dystrophic neurites in the plaques. Double-labeling studies showed t all three of these neuropathological structures also contair

ubiquitin, synaptophysin, and neurofilament (but not tau) immunoreactivity. In contrast, neurofibrillary tangles, neuropil threads, Pick bodies, ballooned neurons, and glia tangles (most of which were tau positive) were NACP negative. These results support the view that NACP specifically accumulates in diseases related to Lewy bodi such as Lewy body variant of Alzheimer's disease, diffus Lewy body disease, and Parkinson's disease and suggests role for this synaptic protein in the pathogenesis of neurodegeneration.

PMID: 9466562 [PubMed - indexed for MEDLINE]

1: Neurosci Lett. 1997 Dec 12;239(1):45-8. Related Articles,

ELSEVIER SCIENCE FULL-TEXT ARTICLE

NACP, a presynaptic protein, immunoreactivity Lewy bodies in Parkinson's disease.

Wakabayashi K, Matsumoto K, Takayama K, Yoshim M, Takahashi H.

Brain Disease Research Center, Niigata University, Japan
koichi@bri.niigata-u.ac.jp

NACP, originally identified as a precursor of the non-Abe component of Alzheimer's disease amyloid (NAC), is nov known to be identical to alpha-synuclein, a presynaptic protein in the human brain. Recently, a mutation in the alp synuclein gene in families with autosomal dominant Parkinson's disease (PD) was identified. We carried out immunohistochemical examinations of the brains of spora PD patients using anti-NACP and anti-ubiquitin antibodie Consistent with previous studies, the anti-NACP antibody immunostained the neuropil in a punctate pattern through the brain. Moreover, much stronger NACP immunoreacti was found in Lewy bodies and degenerating neurites in th brainstem. Serial sections immunolabeled with anti-ubiqu or anti-NACP showed that all ubiquitin-immunoreactive I were also NACP-immunoreactive. These findings suggest that alteration of NACP metabolism is involved in the pathogenesis of PD, particularly in Lewy body formation,

leading to neurodegeneration.

PMID: 9547168 [PubMed - indexed for MEDLINE]

1: Neurosci Lett. 1997 Dec 12;239(1):45-8. Related Articles,

ELSEVIER SCIENCE FULL-TEXT ARTICLE

NACP, a presynaptic protein, immunoreactivity Lewy bodies in Parkinson's disease.

Wakabayashi K, Matsumoto K, Takayama K, Yoshim M, Takahashi H.

Brain Disease Research Center, Niigata University, Japan
koichi@bri.niigata-u.ac.jp

NACP, originally identified as a precursor of the non-Abe component of Alzheimer's disease amyloid (NAC), is nov known to be identical to alpha-synuclein, a presynaptic protein in the human brain. Recently, a mutation in the alp synuclein gene in families with autosomal dominant Parkinson's disease (PD) was identified. We carried out immunohistochemical examinations of the brains of spora PD patients using anti-NACP and anti-ubiquitin antibodie Consistent with previous studies, the anti-NACP antibody immunostained the neuropil in a punctate pattern through the brain. Moreover, much stronger NACP immunoreacti was found in Lewy bodies and degenerating neurites in th brainstem. Serial sections immunolabeled with anti-ubiqu or anti-NACP showed that all ubiquitin-immunoreactive I were also NACP-immunoreactive. These findings suggest that alteration of NACP metabolism is involved in the pathogenesis of PD, particularly in Lewy body formation,

leading to neurodegeneration.

PMID: 9547168 [PubMed - indexed for MEDLINE]

Abnormal distribution of the non-Abeta compor of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment.

Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Sisk A, Masliah E.

Department of Neurosciences, University of California, S Diego, School of Medicine, La Jolla 92093-0624, USA.

The precursor of the non-Abeta component of Alzheimer' disease amyloid (NACP) (also known as alpha-synuclein) presynaptic terminal molecule that abnormally accumulat the plaques of Alzheimer's disease (AD) and in the Lewy bodies (LBs) of Lewy body variant of AD, diffuse Lewy body disease, and Parkinson's disease. To better understar the distribution of NACP/alpha-synuclein and its fragmen the LB-bearing neurons and neurites, as well as to clarify patterns of NACP/alpha-synuclein compartmentalization, studied NACP/alpha-synuclein immunoreactivity using antibodies against the C-terminal, N-terminal, and NAC regions after Proteinase K and formic acid treatment in th cortex of patients with LBs. Furthermore, studies of the subcellular localization of NACP/alpha-synuclein within bearing neurons were performed by immunogold electron

microscopy. These studies showed that the N-terminal antibody immunolabeled the LBs and dystrophic neurites with great intensity and, to a lesser extent, the synapses. I contrast, the C-terminal antibody strongly labeled the synapses and, to a lesser extent, the LBs and dystrophic neurites. Whereas Proteinase K treatment enhanced NACP/alpha-synuclein immunoreactivity with the C-term antibody, it diminished the N-terminal NACP/alpha-synu immunoreactivity. Furthermore, formic acid enhanced LE and dystrophic neurite labeling with both the C- and N-terminal antibodies. In addition, whereas without pretreatment only slight anti-NAC immunoreactivity was found in the LBs, formic acid pretreatment revealed an extensive anti-NAC immunostaining of LBs, plaques, and glial cells. Ultrastructural analysis revealed that NACP/al synuclein immunoreactivity was diffusely distributed wit the amorphous electrodense material in the LBs and as sm clusters in the filaments of LBs and neurites. These result support the view that aggregated NACP/alpha-synuclein might play an important role in the pathogenesis of disord associated with LBs.

PMID: 9759660 [PubMed - indexed for MEDLINE]

1: Acta Neuropathol (Berl). 1998 Nov;96 (5):445-52.

Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy.

Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H.

Brain Disease Research Center, Brain Research Institute, Niigata University, Japan. koichi@bri.niigata-u.ac.jp

Recently, we have shown that the precursor of the non-Al component of Alzheimer's disease amyloid (NACP), also known as alpha-synuclein, is a major component of Lewy bodies (LBs) as well as neuronal and glial cytoplasmic inclusions in multiple system atrophy (MSA). To elucidat whether the accumulation of NACP is specific to LB dise and MSA, we further studied 83 autopsied cases with vari neurological disorders, using anti-NACP antibodies. In LI disease, NACP immunoreactivity was present in all of the LBs and Lewy neurites in both the central and peripheral nervous systems, the pale bodies in the substantia nigra, a dystrophic neurites in the hippocampal CA2/3 region. Immunoelectron microscopy revealed that the reaction product was localized within filamentous structures and associated granular structures. In MSA, NACP

immunoreactivity was found in the intracytoplasmic inclusions of both neuronal and oligodendroglial cells, neuronal intranuclear inclusions, and swollen neuronal processes. No NACP immunoreactivity was found in a variety of other neuronal or glial inclusions in other disor including Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, motor neur disease and triplet-repeat diseases. These findings strongl suggest that the accumulation of NACP is a cytopathologi feature common to LB disease and MSA.

PMID: 9829807 [PubMed - indexed for MEDLINE]

Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy.

Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H.

Brain Disease Research Center, Brain Research Institute, Niigata University, Japan. koichi@bri.niigata-u.ac.jp

Recently, we have shown that the precursor of the non-Al component of Alzheimer's disease amyloid (NACP), also known as alpha-synuclein, is a major component of Lewy bodies (LBs) as well as neuronal and glial cytoplasmic inclusions in multiple system atrophy (MSA). To elucidat whether the accumulation of NACP is specific to LB dise and MSA, we further studied 83 autopsied cases with vari neurological disorders, using anti-NACP antibodies. In LI disease, NACP immunoreactivity was present in all of the LBs and Lewy neurites in both the central and peripheral nervous systems, the pale bodies in the substantia nigra, a dystrophic neurites in the hippocampal CA2/3 region. Immunoelectron microscopy revealed that the reaction product was localized within filamentous structures and associated granular structures. In MSA, NACP

immunoreactivity was found in the intracytoplasmic inclusions of both neuronal and oligodendroglial cells, neuronal intranuclear inclusions, and swollen neuronal processes. No NACP immunoreactivity was found in a variety of other neuronal or glial inclusions in other disor including Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, motor neur disease and triplet-repeat diseases. These findings strongl suggest that the accumulation of NACP is a cytopathologi feature common to LB disease and MSA.

PMID: 9829807 [PubMed - indexed for MEDLINE]

1: Brain Res. 1999 Mar 27;823(1-2):202-6. Related Articles,

Immunohistochemical localization of amyloid be protein with amino-terminal aspartate in the cerebral cortex of patients with Alzheimer's disease.

Arai T, Akiyama H, Ikeda K, Kondo H, Mori H.

Department of Neuropathology, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo 156 8585, Japan. arai@prit.go.jp

We investigated immunohistochemically the localization amyloid beta-protein (Abeta) with amino-terminal asparta (N1[D]) in brains of patients with Alzheimer's disease, diffuse Lewy body disease and Down's syndrome. A monoclonal antibody, 4G8, which recognizes the middle portion of Abeta, was used as a reference antibody to labe the total Abeta deposits. Double staining with anti-Abeta([D]) and 4G8 revealed that Abeta deposits in the subiculu and the neocortical deep layers often lacked N1[D] immunoreactivity, indicating N-terminal truncation of Ab in these deposits. Abeta deposits in the neocortical superf layers and the presubicular parvopyramidal layer always contained Abeta with N1[D]. Such regional as well as lam differences in the distribution of Abeta beginning at N1[D suggest that some local factors influence N-terminal

processing of Abeta deposited in the brain. Copyright 199 Elsevier Science B.V.

PMID: 10095028 [PubMed - indexed for MEDLINE]

1: Neurosci Lett. 1999 May 14;266(3):213-6. Related Articles, ELSEVIER SCIENCE FULL-TEXT ARTICLE

Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bo but not in Alzheimer's disease beta-amyloid plac cores.

Bayer TA, Jakala P, Hartmann T, Havas L, McLean C Culvenor JG, Li QX, Masters CL, Falkai P, Beyreuthe K.

Department of Psychiatry, University of Bonn Medical Center, Germany. bayer@uni-bonn.de

A growing body of evidence suggests that the non-Abeta component of Alzheimer's disease amyloid precursor prot (NACP) or alpha-synuclein contributes to the neurodegenerative processes in Alzheimer's disease (AD) Parkinson's disease (PD) and dementia with Lewy bodies (DLB). In the present study antisera to the N terminus anc NAC domain of the alpha-synuclein protein were employ to elucidate the expression pattern in brains of patients wi AD, PD, DLB and control specimen. Alpha-synuclein exhibited an overall punctuate expression profile compati with a synaptic function. Interestingly, while Lewy bodie were strongly immunoreactive, none of the alpha-synucle antisera revealed staining in mature beta-amyloid plaques AD. These observations suggest that alpha-synuclein doe

contribute to late neurodegenerative processes in AD brai

PMID: 10465711 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Mar 14 2005 07:08:36

1: Arch Neurol. 1999 Sep;56(9):1111-8. Related Articles,

ARCH NEUROL

Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease.

Lippa CF, Ozawa K, Mann DM, Ishii K, Smith TW, Arawaka S, Mori H.

Department of Neurology, MCP-Hahnemann University, Philadelphia, PA 19129, USA. lippa@auhs.edu

BACKGROUND: Alterations in the metabolism of the amyloid precursor protein and the formation of beta-amyl (Abeta) plaques are associated with neuronal death in Alzheimer disease (AD). The plaque subtype Abeta(x-42) occurs as an early event, with Abeta(x-40) plaques formir a later stage. In dementia with Lewy bodies (DLB), an increase in the amount of cortical Abeta occurs without severe cortical neuronal losses. OBJECTIVE: To advance understanding of the natural history of Abeta in neurodegenerative diseases. DESIGN: We evaluated the expression of Abeta(x-40) and Abeta(x-42) in DLB using monoclonal antibodies and immunohistochemical techniq in 5 brain regions. The data were compared with those elicited with normal aging and from patients with AD. SETTING AND PATIENTS: A postmortem study involv 19 patients with DLB without concurrent neuritic

degeneration, 10 patients with AD, and 17 aged persons without dementia for control subjects. RESULTS: The Ab plaques were more numerous in patients with DLB than in controls in most brain regions, although the Abeta(x-42) plaque subtype was predominant in both conditions. Over Abeta(x-42) plaque density was similar in patients with DLB and those with AD, but Abeta(x-40) plaques were more numerous in persons with AD than in those with DLB. The ratio of Abeta(x-40) to Abeta(x-42) plaques was significantly reduced in persons with DLB compared with patients with AD. CONCLUSIONS: The Abeta plaques were more numerous in patients with DLB than persons with normal aging, but the plaque subtypes were similar. The relative proportion of the 2 Abeta plaque subtypes in DLB is distinguishable from that in AD.

PMID: 10488812 [PubMed - indexed for MEDLINE]

1: Arch Neurol. 1999 Sep;56(9):1111-8. Related Articles,

ARCH NEUROL

Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease.

Lippa CF, Ozawa K, Mann DM, Ishii K, Smith TW, Arawaka S, Mori H.

Department of Neurology, MCP-Hahnemann University, Philadelphia, PA 19129, USA. lippa@auhs.edu

BACKGROUND: Alterations in the metabolism of the amyloid precursor protein and the formation of beta-amyl (Abeta) plaques are associated with neuronal death in Alzheimer disease (AD). The plaque subtype Abeta(x-42) occurs as an early event, with Abeta(x-40) plaques formir a later stage. In dementia with Lewy bodies (DLB), an increase in the amount of cortical Abeta occurs without severe cortical neuronal losses. OBJECTIVE: To advance understanding of the natural history of Abeta in neurodegenerative diseases. DESIGN: We evaluated the expression of Abeta(x-40) and Abeta(x-42) in DLB using monoclonal antibodies and immunohistochemical techniq in 5 brain regions. The data were compared with those elicited with normal aging and from patients with AD. SETTING AND PATIENTS: A postmortem study involv 19 patients with DLB without concurrent neuritic

degeneration, 10 patients with AD, and 17 aged persons without dementia for control subjects. RESULTS: The Ab plaques were more numerous in patients with DLB than in controls in most brain regions, although the Abeta(x-42) plaque subtype was predominant in both conditions. Over Abeta(x-42) plaque density was similar in patients with D and those with AD, but Abeta(x-40) plaques were more numerous in persons with AD than in those with DLB. Th ratio of Abeta(x-40) to Abeta(x-42) plaques was significa reduced in persons with DLB compared with patients with AD. CONCLUSIONS: The Abeta plaques were more numerous in patients with DLB than persons with normal aging, but the plaque subtypes were similar. The relative proportion of the 2 Abeta plaque subtypes in DLB is distinguishable from that in AD.

PMID: 10488812 [PubMed - indexed for MEDLINE]

1: Am J Pathol. 1999 Oct;155(4):1173-81. Related Articles,

Comment in:

- Am J Pathol. 2000 Feb;156(2):734-6.

Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synucl are not associated with Abeta amyloid.

Culvenor JG, McLean CA, Cutt S, Campbell BC, Mal F, Jakala P, Hartmann T, Beyreuther K, Masters CL, QX.

Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia.

alpha-Synuclein (alphaSN), also termed the precursor of t non-Abeta component of Alzheimer's disease (AD) amylc (NACP), is a major component of Lewy bodies and Lewy neurites pathognomonic of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). A fragment of alphaS termed the non-Abeta component of AD amyloid (NAC) previously been identified as a constituent of AD amyloid plaques. To clarify the relationship of NAC and alphaSN Abeta plaques, antibodies were raised to three domains of alphaSN. All antibodies produced punctate labeling of hu cortex and strong labeling of Lewy bodies. Using antibod

to alphaSN(75-91) to label cortical and hippocampal secti of pathologically proven AD cases, we found no evidence NAC in Abeta amyloid plaques. Double labeling of tissue sections in mixed DLB/AD cases revealed alphaSN in dystrophic neuritic processes, some of which were in clos association with Abeta plaques restricted to the CA1 hippocampal region. In brain homogenates alphaSN was predominantly recovered in the cytosolic fraction as a 16- protein on Western analysis; however, significant amount aggregated and alphaSN fragments were also found in ure extracts of SDS-insoluble material from DLB and PD cas NAC antibodies identified an endogenous fragment of 6 k the cytosolic and urea-soluble brain fractions. This fragm may be produced as a consequence of alphaSN aggregatic alternatively may accelerate aggregation of the full-length alphaSN.

PMID: 10514400 [PubMed - indexed for MEDLINE]

1: Am J Pathol. 1999 Oct;155(4):1173-81. Related Articles,

Comment in:

- Am J Pathol. 2000 Feb;156(2):734-6.

Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synucl are not associated with Abeta amyloid.

Culvenor JG, McLean CA, Cutt S, Campbell BC, Mal F, Jakala P, Hartmann T, Beyreuther K, Masters CL, QX.

Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia.

alpha-Synuclein (alphaSN), also termed the precursor of t non-Abeta component of Alzheimer's disease (AD) amylc (NACP), is a major component of Lewy bodies and Lewy neurites pathognomonic of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). A fragment of alphaS termed the non-Abeta component of AD amyloid (NAC) previously been identified as a constituent of AD amyloid plaques. To clarify the relationship of NAC and alphaSN Abeta plaques, antibodies were raised to three domains of alphaSN. All antibodies produced punctate labeling of hu cortex and strong labeling of Lewy bodies. Using antibod

to alphaSN(75-91) to label cortical and hippocampal secti of pathologically proven AD cases, we found no evidence NAC in Abeta amyloid plaques. Double labeling of tissue sections in mixed DLB/AD cases revealed alphaSN in dystrophic neuritic processes, some of which were in clos association with Abeta plaques restricted to the CA1 hippocampal region. In brain homogenates alphaSN was predominantly recovered in the cytosolic fraction as a 16- protein on Western analysis; however, significant amount aggregated and alphaSN fragments were also found in ure extracts of SDS-insoluble material from DLB and PD cas NAC antibodies identified an endogenous fragment of 6 k the cytosolic and urea-soluble brain fractions. This fragm may be produced as a consequence of alphaSN aggregatic alternatively may accelerate aggregation of the full-length alphaSN.

PMID: 10514400 [PubMed - indexed for MEDLINE]

1: Brain Res. 1999 Oct 2;843(1-2):53-61. Related Articles,

ELSEVIER SCIENCE FULL-TEXT ARTICLE

Cellular co-localization of phosphorylated tau- a NACP/alpha-synuclein-epitopes in lewy bodies i sporadic Parkinson's disease and in dementia wi Lewy bodies.

Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Ueda K, Ikeda K, Kawai M.

Department of Ultrastructure and Histochemistry, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo, Japan. arima@prit.go.jp

The precursor of the non-Abeta-component of Alzheimer' disease (AD) amyloid (NACP, alpha-synuclein) aggregate into insoluble filaments of Lewy bodies (LBs) in Parkinso disease (PD) and dementia with LBs (DLB). The microtubule-associated protein tau is an integral compone of filaments of neurofibrillary tangles (NFTs). NFTs are occasionally found in brains of PD and DLB; however, th presence of NFTs or tau-epitopes within LB-containing neurons is rare. Double-immunofluorescence study and peroxidase-immunohistochemical study in serial sections, performed to examine the co-localization of tau- and NAC epitopes in the brainstem of PD and DLB, demonstrated t four different epitopes of tau including phosphorylation-dependent and independent ones were present in a minori

LBs, but more often than previously considered. A tau (ta epitope was localized to filaments in the outer layers of brainstem-type LBs by immunoelectron microscopy. Therefore, we conclude that tau is incorporated into filam in certain LBs. Extensive investigation has enabled us to classify this co-localization into four types: type 1, LBs w ring-shaped tau-immunoreactivity; type 2, LBs surrounde NFTs; type 3, NACP- and tau-immunoreactive filamento and granular masses; and type 4, NACP- and tau-immunoreactive dystrophic neurites. This study raises a n question whether aggregation and hyperphosphorylation c tau in PD and DLB are triggered by the collapse of intraneuronal organization of microtubules due to NACP-filament aggregation in neuronal perikarya and axons.

PMID: 10528110 [PubMed - indexed for MEDLINE]

1: Brain Res. 1999 Oct 2;843(1-2):53-61. Related Articles,

ELSEVIER SCIENCE FULL-TEXT ARTICLE

Cellular co-localization of phosphorylated tau- a NACP/alpha-synuclein-epitopes in lewy bodies i sporadic Parkinson's disease and in dementia wi Lewy bodies.

Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Ueda K, Ikeda K, Kawai M.

Department of Ultrastructure and Histochemistry, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo, Japan. arima@prit.go.jp

The precursor of the non-Abeta-component of Alzheimer' disease (AD) amyloid (NACP, alpha-synuclein) aggregate into insoluble filaments of Lewy bodies (LBs) in Parkinso disease (PD) and dementia with LBs (DLB). The microtubule-associated protein tau is an integral compone of filaments of neurofibrillary tangles (NFTs). NFTs are occasionally found in brains of PD and DLB; however, th presence of NFTs or tau-epitopes within LB-containing neurons is rare. Double-immunofluorescence study and peroxidase-immunohistochemical study in serial sections, performed to examine the co-localization of tau- and NAC epitopes in the brainstem of PD and DLB, demonstrated t four different epitopes of tau including phosphorylation-dependent and independent ones were present in a minori

LBs, but more often than previously considered. A tau (ta epitope was localized to filaments in the outer layers of brainstem-type LBs by immunoelectron microscopy. Therefore, we conclude that tau is incorporated into filam in certain LBs. Extensive investigation has enabled us to classify this co-localization into four types: type 1, LBs w ring-shaped tau-immunoreactivity; type 2, LBs surrounde NFTs; type 3, NACP- and tau-immunoreactive filamento and granular masses; and type 4, NACP- and tau-immunoreactive dystrophic neurites. This study raises a n question whether aggregation and hyperphosphorylation c tau in PD and DLB are triggered by the collapse of intraneuronal organization of microtubules due to NACP-filament aggregation in neuronal perikarya and axons.

PMID: 10528110 [PubMed - indexed for MEDLINE]

1: Neuropathol Appl Neurobiol. 1999 Oct;25 (5):363-8.

Widespread occurrence of alpha-synuclein/NAC immunoreactive neuronal inclusions in juvenile adult-onset Hallervorden-Spatz disease with Lev bodies.

Wakabayashi K, Yoshimoto M, Fukushima T, Koide I Horikawa Y, Morita T, Takahashi H.

Brain Disease Research Center, Brain Research Institute, Niigata University, Japan.

Alpha-Synuclein (originally called precursor of the non-Abeta component of Alzheimer's disease amyloid-NACP) presynaptic nerve terminal protein and is now known to b major component of Lewy bodies (LBs) in Parkinson's disease. Previous studies have shown that LBs are occasionally found in patients with Hallervorden-Spatz disease (HSD), a hereditary or sporadic neuroaxonal dystrophy. Therefore, an immunocytochemical examinati of the brain tissues from two patients with HSD for alpha-synuclein/NACP was performed. In both cases, LBs were observed in the substantia nigra, locus ceruleus and other subcortical nuclei. These LBs were strongly immunolabel with anti-alpha-synuclein/NACP. Moreover, abnormal alp

synuclein/NACP-immunoreactive structures in the neuror somata and processes were found in the cerebral neocorte hippocampus, basal ganglia, thalamus, pontine and inferic olivary nuclei, spinal grey matter, and peripheral sympath ganglia. Although numerous dystrophic axons (spheroids) were found throughout the brain, either none or only a fev were positive for alpha-synuclein/NACP. These findings suggest that widespread accumulation of alpha-synuclein/NACP is a pathological feature in patients suffe from HSD with LBs, and that this phenomenon is unrelate axonal spheroid formation.

PMID: 10564525 [PubMed - indexed for MEDLINE]

ACS PUBLICATIONS

Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease typical amyloid.

Conway KA, Harper JD, Lansbury PT Jr.

Center for Neurologic Diseases, Brigham and Women's Hospital and Department of Neurology, Harvard Medical School, Boston, Massachusetts 02115, USA.

Two missense mutations in the gene encoding alpha-synuclein have been linked to rare, early-onset forms of Parkinson's disease (PD). These forms of PD, as well as tl common idiopathic form, are characterized by the presenc cytoplasmic neuronal deposits, called Lewy bodies, in the affected region of the brain. Lewy bodies contain alpha-synuclein in a form that resembles fibrillar Abeta derived from Alzheimer's disease (AD) amyloid plaques. One of t mutant forms of alpha-synuclein (A53T) fibrillizes more rapidly in vitro than does the wild-type protein, suggestin that a correlation may exist between the rate of in vitro fibrillization and/or oligomerization and the progression c PD, analogous to the relationship between Abeta fibrilliza in vitro and familial AD. In this paper, fibrils generated in

vitro from alpha-synuclein, wild-type and both mutant for are shown to possess very similar features that are characteristic of amyloid fibrils, including a wound and predominantly unbranched morphology (demonstrated by atomic force and electron microscopies), distinctive dye-binding properties (Congo red and thioflavin T), and antiparallel beta-sheet structure (Fourier transform infrare spectroscopy and circular dichroism spectroscopy). alpha-Synuclein fibrils are relatively resistant to proteolysis, a property shared by fibrillar Abeta and the disease-associat fibrillar form of the prion protein. These data suggest that like AD, is a brain amyloid disease that, unlike AD, is characterized by cytoplasmic amyloid (Lewy bodies). In addition to amyloid fibrils, a small oligomeric form of alp synuclein, which may be analogous to the Abeta protofibr was observed prior to the appearance of fibrils. This speci or a related one, rather than the fibril itself, may be responsible for neuronal death.

PMID: 10704204 [PubMed - indexed for MEDLINE]

1: Neurobiol Dis. 2000 Jun;7(3):192-200. Related Articles,

ELSEVIER SCIENCE FULL-TEXT ARTICLE

Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies.

Campbell BC, Li QX, Culvenor JG, Jakala P, Cappai Beyreuther K, Masters CL, McLean CA.

Department of Pathology, The University of Melbourne, 3010, Australia.

The alpha-synuclein (alpha SN) protein is thought to play central role in the pathogenesis of neurodegenerative dise where it aggregates to form intracellular inclusions. We h used Western blotting to examine the expression levels ar solubility of alpha SN in brain homogenates from dement with Lewy bodies (DLB), Parkinson's disease (PD), Alzheimer's disease (AD), and normal controls using sam from the parahippocampus/transentorhinal cortex. Compa to controls, DLB brains accumulate significantly greater amounts of sodium dodecyl sulfate (SDS)-soluble and SD insoluble alpha SN but levels of TBS-soluble alpha SN di not change. Levels of synaptophysin, a marker of synaptic integrity, were significantly lower in DLB cases than in normal aged controls regardless of whether concurrent changes of AD were present. This limbic synaptic dysfunction may contribute to cognitive impairment in DI Whether aggregated alpha SN is a cause or effect of the

disease process in DLB and PD remains to be determined the presence of aggregated alpha SN is consistent with a pathogenesis similar to that associated with aggregates of Abeta amyloid in AD. Copyright 2000 Academic Press.

PMID: 10860784 [PubMed - indexed for MEDLINE]

1: J Neurosci Res. 2000 Jul 15;61(2):121-7. Related Articles, InterScience

Neuropathology of synuclein aggregates.

Duda JE, Lee VM, Trojanowski JQ.

Center For Neurodegenerative Disease Research, Univers of Pennsylvania School of Medicine, Philadelphia, PA 19 USA.

Beginning with the isolation of the fragment of alpha-synuclein (alpha-syn) known as the non-Abeta componen amyloid plaques (NAC peptide) from Alzheimer's disease (AD) brains, alpha-syn has been increasingly implicated i the pathogenesis of neurodegenerative diseases, which no are classified as synucleinopathies. Indeed, unequivocal evidence linking abnormal alpha-syn to mechanisms of br degeneration came from discoveries of missense mutation the alpha-syn gene pathogenic for familial Parkinson's dis (PD) in rare kindreds. Shortly thereafter, alpha-syn was shown to be a major component of Lewy bodies (LBs) an Lewy neurites in sporadic PD, dementia with LBs (DLB) the LB variant of AD. Also, studies of brains from patient with AD caused by genetic abnormalities demonstrated m alpha-syn positive LBs. Further, alpha-syn was implicated the formation of the glial (GCIs) and neuronal cytoplasmi inclusions of multiple system atrophy, and the LBs, GCIs neuraxonal spheroids of neurodegeneration with brain iro

accumulation type 1. Recently, two other members of the synuclein family, beta- and gamma-synuclein, have also b recognized to play a role in the pathogenesis of novel axo lesions in PD and DLB. Evidence for a role of alpha-syn i the formation of filamentous aggregates was reinforced b vitro studies showing aggregation and fibrillogenesis of mutant and wild type alpha-syn. Indeed, since the aggrega of brain proteins into presumptively toxic lesions is emerg as a common but poorly understood mechanistic theme in sporadic and hereditary neurodegenerative diseases, clarification of the mechanism of synuclein aggregation c augment efforts to develop novel and more effective thera for many neurodegenerative disorders.

Publication Types:

- Review
- Review, Tutorial

PMID: 10878583 [PubMed - indexed for MEDLINE]

1: J Mol Neurosci. 2001 Oct;17(2):225-32. Related Articles,

HUMANA PRESS
SCIENTIFIC AND MEDICAL PUBLISHERS

Lewy body pathology in Alzheimer's disease.

Kotzbauer PT, Trojanowsk JQ, Lee VM.

Center for Neurodegenerative Disease Research, Universi of Pennsylvania School of Medicine, Philadelphia, USA.

Lewy bodies, the characteristic pathological lesion of substantia nigra neurons in Parkinson's disease (PD), are frequently observed to accompany the amyloid plaque an neurofibrillary tangle pathology of Alzheimer's disease (A However the typical anatomic distribution of Lewy bodie AD is distinct from PD. The most common site of occurre is the amygdala, where Lewy bodies are observed in approximately 60% of both sporadic and familial AD. Otl common sites of occurrence include the periamygdaloid a entorhinal cortex, while neocortical and brainstem areas develop Lewy bodies in a lower percentage of cases. In contrast, dementia with Lewy bodies (DLB), defined by widespread neocortical and brainstem Lewy bodies but frequently accompanied by variable levels of AD-type pathology, represents the other end of a spectrum of pathology associated with dementia. The observation of L bodies in familial AD cases suggests that like neurofibrill tangles, the formation of Lewy bodies can be induced by pathological state caused by Abeta-amyloid overproducti

The role of Lewy body formation in the dysfunction and degeneration of neurons remains unclear. The protein alpl synuclein appears to be an important structural componen Lewy bodies, an observation spurred by the discovery of point mutations in the alpha-synuclein gene linked to rare cases of autosomal dominant PD. Further investigation of alpha-synuclein and its relationship to pathological condit promoting Lewy body formation in AD, PD, and DLB ma yield further insight into pathogenesis of these diseases.

Publication Types:

- Review
- Review, Tutorial

PMID: 11816795 [PubMed - indexed for MEDLINE]

NCBI PubMed National Library of Medicine NLM [Sign In]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journal

Search PubMed for alpha-synuclein AND abeta Go Clear Sav

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)
Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

All: 77 Review: 17

Items 1 - 77 of 77 One p

1: Mikolaenko I, Pletnikova O, Kawas CH, O'Brien R, Resnick SM, Crain B, Troncoso JC. Related Articles, l

Alpha-synuclein lesions in normal aging, Parkinson dise and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA).
J Neuropathol Exp Neurol. 2005 Feb;64(2):156-62.
PMID: 15751230 [PubMed - in process]

2: Bisaglia M, Trolio A, Tessari I, Bubacco L, Mammi S, Bergantino E. Related Articles, l

Cloning, expression, purification, and spectroscopic anal of the fragment 57-102 of human alpha-synuclein.
Protein Expr Purif. 2005 Jan;39(1):90-6.
PMID: 15596364 [PubMed - in process]

3: Wacker JL, Zareie MH, Fong H, Sarikaya M, Muchowski PJ. Related Articles, l

Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monom
Nat Struct Mol Biol. 2004 Dec;11(12):1215-22. Epub 2004 Nov
PMID: 15543156 [PubMed - indexed for MEDLINE]

4: Khan A, Ashcroft AE, Korchazhkina OV, Exley C. Related Articles, l

Metal-mediated formation of fibrillar ABri amyloid.
J Inorg Biochem. 2004 Dec;98(12):2006-10.
PMID: 15541488 [PubMed - indexed for MEDLINE]

5: van Horssen J, de Vos RA, Steur EN, David G, Wesseling P, de Waal RM, Verbeek MM. Related Articles, l

Absence of heparan sulfate proteoglycans in Lewy bodie

and Lewy neurites in Parkinson's disease brains.
J Alzheimers Dis. 2004 Oct;6(5):469-74.
PMID: 15505367 [PubMed - indexed for MEDLINE]

☐ **6:** Diaz-Hernandez M, Moreno-Herrero F, Gomez-Ramos P, Moran MA, Ferrer I, Baro AM, Avila J, Hernandez F, Lucas JJ. Related Articles, I

Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human bra
J Neurosci. 2004 Oct 20;24(42):9361-71.
PMID: 15496672 [PubMed - in process]

☐ **7:** Lee D, Paik SR, Choi KY. Related Articles, I

Beta-synuclein exhibits chaperone activity more efficien than alpha-synuclein.
FEBS Lett. 2004 Oct 8;576(1-2):256-60.
PMID: 15474047 [PubMed - indexed for MEDLINE]

☐ **8:** Windisch M, Hutter-Paier B, Schreiner E, Wronski R. Related Articles, I

Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?
J Mol Neurosci. 2004;24(1):155-65.
PMID: 15314265 [PubMed - indexed for MEDLINE]

☐ **9:** Li Q, Cao C, Chackerian B, Schiller J, Gordon M, Ugen KE, Morgan D. Related Articles, I

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-l particles in amyloidbeta immunized amyloid precursor protein transgenic mice.
BMC Neurosci. 2004 Jun 8;5(1):21.
PMID: 15186505 [PubMed - indexed for MEDLINE]

☐ **10:** Capanni C, Taddei N, Gabrielli S, Messori L, Orioli P, Chiti F, Stefani M, Ramponi G. Related Articles, I

Investigation of the effects of copper ions on protein aggregation using a model system.
Cell Mol Life Sci. 2004 Apr;61(7-8):982-91.
PMID: 15095018 [PubMed - indexed for MEDLINE]

☐ **11:** Li J, Zhu M, Manning-Bog AB, Di Monte Related Articles, I

DA, Fink AL.

Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease.
FASEB J. 2004 Jun;18(9):962-4. Epub 2004 Apr 1.
PMID: 15059976 [PubMed - indexed for MEDLINE]

☐ **12:** Bodles AM, El-Agnaf OM, Greer B, Guthrie DJ, Irvine GB. Related Articles, l

Inhibition of fibril formation and toxicity of a fragment alpha-synuclein by an N-methylated peptide analogue.
Neurosci Lett. 2004 Apr 8;359(1-2):89-93.
PMID: 15050719 [PubMed - indexed for MEDLINE]

☐ **13:** Lee EN, Cho HJ, Lee CH, Lee D, Chung KC, Paik SR. Related Articles, l

Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of alpha-synuclein.
Biochemistry. 2004 Mar 30;43(12):3704-15.
PMID: 15035641 [PubMed - indexed for MEDLINE]

☐ **14:** Hamilton RL, Bowser R. Related Articles, l

Alzheimer disease pathology in amyotrophic lateral sclerosis.
Acta Neuropathol (Berl). 2004 Jun;107(6):515-22. Epub 2004 M 16.
PMID: 15024584 [PubMed - indexed for MEDLINE]

☐ **15:** Chirita C, Necula M, Kuret J. Related Articles, l

Ligand-dependent inhibition and reversal of tau filamer formation.
Biochemistry. 2004 Mar 16;43(10):2879-87.
PMID: 15005623 [PubMed - indexed for MEDLINE]

☐ **16:** Singleton A, Myers A, Hardy J. Related Articles, l

The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases.
Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R123-6. Epub 2004 19. Review.
PMID: 14976159 [PubMed - indexed for MEDLINE]

☐ **17:** Related Articles, l

Kuroda Y, Maeda Y, Hanaoka H, Miyamoto

K, Nakagawa T.

Oligopeptide-mediated acceleration of amyloid fibril formation of amyloid beta(Abeta) and alpha-synuclein fragment peptide (NAC).
J Pept Sci. 2004 Jan;10(1):8-17.
PMID: 14959887 [PubMed - indexed for MEDLINE]

☐ **18:** Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, Jensen PH. Related Articles, l

Proteasomal inhibition by alpha-synuclein filaments an oligomers.
J Biol Chem. 2004 Mar 26;279(13):12924-34. Epub 2004 Jan 7
PMID: 14711827 [PubMed - indexed for MEDLINE]

☐ **19:** Cheng SY, Trombetta LD. Related Articles, l

The induction of amyloid precursor protein and alpha-synuclein in rat hippocampal astrocytes by diethyldithiocarbamate and copper with or without glutathione.
Toxicol Lett. 2004 Jan 15;146(2):139-49.
PMID: 14643966 [PubMed - indexed for MEDLINE]

☐ **20:** Hashimoto M, Masliah E. Related Articles, l

Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with L bodies.
Neurochem Res. 2003 Nov;28(11):1743-56. Review.
PMID: 14584828 [PubMed - indexed for MEDLINE]

☐ **21:** Smith DH, Uryu K, Saatman KE, Trojanowski JQ, McIntosh TK. Related Articles, l

Protein accumulation in traumatic brain injury.
Neuromolecular Med. 2003;4(1-2):59-72. Review.
PMID: 14528053 [PubMed - indexed for MEDLINE]

☐ **22:** Giasson BI, Lee VM, Trojanowski JQ. Related Articles, l

Interactions of amyloidogenic proteins.
Neuromolecular Med. 2003;4(1-2):49-58. Review.
PMID: 14528052 [PubMed - indexed for MEDLINE]

☐ **23:** Hashimoto M, Rockenstein E, Crews L, Masliah E. Related Articles, l

Role of protein aggregation in mitochondrial dysfunctic and neurodegeneration in Alzheimer's and Parkinson's diseases.
Neuromolecular Med. 2003;4(1-2):21-36. Review.
PMID: 14528050 [PubMed - indexed for MEDLINE]

☐ **24:** Turnbull S, Tabner BJ, Brown DR, Allsop D. Related Articles, I

Quinacrine acts as an antioxidant and reduces the toxici of the prion peptide PrP106-126.
Neuroreport. 2003 Sep 15;14(13):1743-5.
PMID: 14512849 [PubMed - indexed for MEDLINE]

☐ **25:** Yokota O, Terada S, Ishizu H, Ujike H, Ishihara T, Namba M, Hayashi Y, Nishinaka T, Namba R, Nakashima H, Ueda K, Checler F, Kuroda S. Related Articles, I

Variability and heterogeneity in Alzheimer's disease wi cotton wool plaques: a clinicopathological study of fou autopsy cases.
Acta Neuropathol (Berl). 2003 Oct;106(4):348-56. Epub 2003 J 16.
PMID: 12883830 [PubMed - indexed for MEDLINE]

☐ **26:** Hashimoto M, Rockenstein E, Masliah E. Related Articles, I

Transgenic models of alpha-synuclein pathology: past, present, and future.
Ann N Y Acad Sci. 2003 Jun;991:171-88. Review.
PMID: 12846986 [PubMed - indexed for MEDLINE]

☐ **27:** Hashimoto Y, Niikura T, Chiba T, Tsukamoto E, Kadowaki H, Nishitoh H, Yamagishi Y, Ishizaka M, Yamada M, Nawa M, Terashita K, Aiso S, Ichijo H, Nishimoto I. Related Articles, I

The cytoplasmic domain of Alzheimer's amyloid-beta protein precursor causes sustained apoptosis signal-regulating kinase 1/c-Jun NH2-terminal kinase-mediate neurotoxic signal via dimerization.
J Pharmacol Exp Ther. 2003 Sep;306(3):889-902. Epub 2003 Ju 26.
PMID: 12829723 [PubMed - indexed for MEDLINE]

☐ **28:** Krass KL, Colinayo V, Ghazalpour A, Vinters HV, Lusis AJ, Drake TA. Related Articles, l

Genetic loci contributing to age-related hippocampal lesions in mice.
Neurobiol Dis. 2003 Jul;13(2):102-8.
PMID: 12828934 [PubMed - indexed for MEDLINE]

☐ **29:** Turnbull S, Tabner BJ, Brown DR, Allsop D. Related Articles, l

Generation of hydrogen peroxide from mutant forms of prion protein fragment PrP121-231.
Biochemistry. 2003 Jul 1;42(25):7675-81.
PMID: 12820876 [PubMed - indexed for MEDLINE]

☐ **30:** Hardy J. Related Articles, l

The relationship between amyloid and tau.
J Mol Neurosci. 2003 Apr;20(2):203-6. Review.
PMID: 12794314 [PubMed - indexed for MEDLINE]

☐ **31:** Powers JM, Byrne NP, Ito M, Takao M, Yankopoulou D, Spillantini MG, Ghetti B. Related Articles, l

A novel leukoencephalopathy associated with tau depos primarily in white matter glia.
Acta Neuropathol (Berl). 2003 Aug;106(2):181-7. Epub 2003 M 29.
PMID: 12783250 [PubMed - indexed for MEDLINE]

☐ **32:** Ma QL, Chan P, Yoshii M, Ueda K. Related Articles, l

Alpha-synuclein aggregation and neurodegenerative diseases.
J Alzheimers Dis. 2003 Apr;5(2):139-48. Review.
PMID: 12719631 [PubMed - indexed for MEDLINE]

☐ **33:** Wirths O, Bayer TA. Related Articles, l

Alpha-synuclein, Abeta and Alzheimer's disease.
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):1 8. Review.
PMID: 12551731 [PubMed - indexed for MEDLINE]

☐ **34:** Terada S, Ishizu H, Yokota O, Tsuchiya K, Nakashima H, Ishihara T, Fujita D, Ueda K, Ikeda K, Kuroda S. Related Articles, l

Glial involvement in diffuse Lewy body disease.

Acta Neuropathol (Berl). 2003 Feb;105(2):163-9. Epub 2002 O 25.
PMID: 12536227 [PubMed - indexed for MEDLINE]

☐ **35:** Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA. Related Articles, I

Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease.
Mov Disord. 2003 Jan;18(1):81-6.
PMID: 12518303 [PubMed - indexed for MEDLINE]

☐ **36:** Turnbull S, Tabner BJ, Brown DR, Allsop D. Related Articles, I

Copper-dependent generation of hydrogen peroxide fro the toxic prion protein fragment PrP106-126.
Neurosci Lett. 2003 Jan 23;336(3):159-62.
PMID: 12505617 [PubMed - indexed for MEDLINE]

☐ **37:** Trojanowski JQ. Related Articles, I

"Emerging Alzheimer's disease therapies: focusing on t future".
Neurobiol Aging. 2002 Nov-Dec;23(6):985-90.
PMID: 12470793 [PubMed - indexed for MEDLINE]

☐ **38:** Yokota O, Terada S, Ishizu H, Ujike H, Ishihara T, Nakashima H, Yasuda M, Kitamura Y, Ueda K, Checler F, Kuroda S. Related Articles, I

NACP/alpha-synuclein, NAC, and beta-amyloid pathol of familial Alzheimer's disease with the E184D presenil 1 mutation: a clinicopathological study of two autopsy cases.
Acta Neuropathol (Berl). 2002 Dec;104(6):637-48. Epub 2002 . 14.
PMID: 12410385 [PubMed - indexed for MEDLINE]

☐ **39:** Forloni G, Terreni L, Bertani I, Fogliarino S, Invernizzi R, Assini A, Ribizzi G, Negro A, Calabrese E, Volonte MA, Mariani C, Franceschi M, Tabaton M, Bertoli A. Related Articles, I

Protein misfolding in Alzheimer's and Parkinson's disea genetics and molecular mechanisms.
Neurobiol Aging. 2002 Sep-Oct;23(5):957-76. Review.
PMID: 12392798 [PubMed - indexed for MEDLINE]

☐ **40:** Xu G, Gonzales V, Borchelt DR. Related Articles, l

Rapid detection of protein aggregates in the brains of Alzheimer patients and transgenic mouse models of amyloidosis.
Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):191-5.
PMID: 12218651 [PubMed - indexed for MEDLINE]

☐ **41:** Xia Y, Saitoh T, Ueda K, Tanaka S, Chen X, Hashimoto M, Hsu L, Conrad C, Sundsmo M, Yoshimoto M, Thal L, Katzman R, Masliah E. Related Articles, l

Characterization of the human alpha-synuclein gene: Genomic structure, transcription start site, promoter reg and polymorphisms.
J Alzheimers Dis. 2001 Oct;3(5):485-494.
PMID: 12214035 [PubMed - as supplied by publisher]

☐ **42:** Yokota O, Terada S, Ishizu H, Tsuchiya K, Kitamura Y, Ikeda K, Ueda K, Kuroda S. Related Articles, l

NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC).
Acta Neuropathol (Berl). 2002 Oct;104(4):333-41. Epub 2002 M 8.
PMID: 12200618 [PubMed - indexed for MEDLINE]

☐ **43:** Eakin CM, Knight JD, Morgan CJ, Gelfand MA, Miranker AD. Related Articles, l

Formation of a copper specific binding site in non-nativ states of beta-2-microglobulin.
Biochemistry. 2002 Aug 27;41(34):10646-56.
PMID: 12186550 [PubMed - indexed for MEDLINE]

☐ **44:** Goldstine J, Seligson DB, Beizai P, Miyata H, Vinters HV. Related Articles, l

Tissue microarrays in the study of non-neoplastic disea of the nervous system.
J Neuropathol Exp Neurol. 2002 Aug;61(8):653-62. Review.
PMID: 12152780 [PubMed - indexed for MEDLINE]

☐ **45:** Tanaka S, Takehashi M, Matoh N, Iida S, Suzuki T, Futaki S, Hamada H, Masliah E, Sugiura Y, Ueda K. Related Articles, l

Generation of reactive oxygen species and activation of NF-kappaB by non-Abeta component of Alzheimer's disease amyloid.
J Neurochem. 2002 Jul;82(2):305-15.
PMID: 12124431 [PubMed - indexed for MEDLINE]

☐ **46:** Tabner BJ, Turnbull S, El-Agnaf O, Allsop D. Related Articles, l

Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases.
Curr Top Med Chem. 2001 Dec;1(6):507-17. Review.
PMID: 11895127 [PubMed - indexed for MEDLINE]

☐ **47:** Ahn BH, Rhim H, Kim SY, Sung YM, Lee MY, Choi JY, Wolozin B, Chang JS, Lee YH, Kwon TK, Chung KC, Yoon SH, Hahn SJ, Kim MS, Jo YH, Min do S. Related Articles, l

alpha-Synuclein interacts with phospholipase D isozym and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells.
J Biol Chem. 2002 Apr 5;277(14):12334-42. Epub 2002 Jan 30
PMID: 11821392 [PubMed - indexed for MEDLINE]

☐ **48:** Kotzbauer PT, Trojanowsk JQ, Lee VM. Related Articles, l

Lewy body pathology in Alzheimer's disease.
J Mol Neurosci. 2001 Oct;17(2):225-32. Review.
PMID: 11816795 [PubMed - indexed for MEDLINE]

☐ **49:** Li G, Zhou P, Shao Z, Xie X, Chen X, Wang H, Chunyu L, Yu T. Related Articles, l

The natural silk spinning process. A nucleation-dependa aggregation mechanism?
Eur J Biochem. 2001 Dec;268(24):6600-6.
PMID: 11737214 [PubMed - indexed for MEDLINE]

☐ **50:** Tomidokoro Y, Harigaya Y, Matsubara E, Ikeda M, Kawarabayashi T, Shirao T, Ishiguro K, Okamoto K, Younkin SG, Shoji M. Related Articles, l

Brain Abeta amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau.

J Pathol. 2001 Aug;194(4):500-6.
PMID: 11523060 [PubMed - indexed for MEDLINE]

☐ **51:** Bodles AM, Guthrie DJ, Greer B, Irvine GB. Related Articles, I

Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for i aggregation and toxicity.
J Neurochem. 2001 Jul;78(2):384-95.
PMID: 11461974 [PubMed - indexed for MEDLINE]

☐ **52:** Ferrer I. Related Articles, I

[Alpha-synucleinopathies]
Neurologia. 2001 Apr;16(4):163-70. Review. Spanish.
PMID: 11412709 [PubMed - indexed for MEDLINE]

☐ **53:** Terai K, Iwai A, Kawabata S, Tasaki Y, Watanabe T, Miyata K, Yamaguchi T. Related Articles, I

beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease.
Neuroscience. 2001;104(2):299-310.
PMID: 11377835 [PubMed - indexed for MEDLINE]

☐ **54:** Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, Allsop D. Related Articles, I

alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro.
Free Radic Biol Med. 2001 May 15;30(10):1163-70.
PMID: 11369507 [PubMed - indexed for MEDLINE]

☐ **55:** El-Agnaf OM, Irvine GB. Related Articles, I

Review: formation and properties of amyloid-like fibril derived from alpha-synuclein and related proteins.
J Struct Biol. 2000 Jun;130(2-3):300-9. Review.
PMID: 10940234 [PubMed - indexed for MEDLINE]

☐ **56:** Askanas V, Engel WK, Alvarez RB, McFerrin J, Broccolini A. Related Articles, I

Novel immunolocalization of alpha-synuclein in humar muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions.
J Neuropathol Exp Neurol. 2000 Jul;59(7):592-8.

PMID: 10901230 [PubMed - indexed for MEDLINE]

☐ **57:** Yamazaki M, Arai Y, Baba M, Iwatsubo T, Mori O, Katayama Y, Oyanagi K. Related Articles, I

Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam.
J Neuropathol Exp Neurol. 2000 Jul;59(7):585-91.
PMID: 10901229 [PubMed - indexed for MEDLINE]

☐ **58:** Iwai A. Related Articles, I

Properties of NACP/alpha-synuclein and its role in Alzheimer's disease.
Biochim Biophys Acta. 2000 Jul 26;1502(1):95-109. Review.
PMID: 10899435 [PubMed - indexed for MEDLINE]

☐ **59:** Duda JE, Lee VM, Trojanowski JQ. Related Articles, I

Neuropathology of synuclein aggregates.
J Neurosci Res. 2000 Jul 15;61(2):121-7. Review.
PMID: 10878583 [PubMed - indexed for MEDLINE]

☐ **60:** Campbell BC, Li QX, Culvenor JG, Jakala P, Cappai R, Beyreuther K, Masters CL, McLean CA. Related Articles, I

Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies.
Neurobiol Dis. 2000 Jun;7(3):192-200.
PMID: 10860784 [PubMed - indexed for MEDLINE]

☐ **61:** Bodles AM, Guthrie DJ, Harriott P, Campbell P, Irvine GB. Related Articles, I

Toxicity of non-abeta component of Alzheimer's diseas amyloid, and N-terminal fragments thereof, correlates t formation of beta-sheet structure and fibrils.
Eur J Biochem. 2000 Apr;267(8):2186-94.
PMID: 10759841 [PubMed - indexed for MEDLINE]

☐ **62:** Conway KA, Harper JD, Lansbury PT Jr. Related Articles, I

Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Biochemistry. 2000 Mar 14;39(10):2552-63.

PMID: 10704204 [PubMed - indexed for MEDLINE]

☐ **63:** Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. Related Articles, l

NACP/alpha-synuclein-positive filamentous inclusions astrocytes and oligodendrocytes of Parkinson's disease brains.
Acta Neuropathol (Berl). 2000 Jan;99(1):14-20.
PMID: 10651022 [PubMed - indexed for MEDLINE]

☐ **64:** Wakabayashi K, Yoshimoto M, Fukushima T, Koide R, Horikawa Y, Morita T, Takahashi H. Related Articles, l

Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adu onset Hallervorden-Spatz disease with Lewy bodies.
Neuropathol Appl Neurobiol. 1999 Oct;25(5):363-8.
PMID: 10564525 [PubMed - indexed for MEDLINE]

☐ **65:** Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Ueda K, Ikeda K, Kawai M. Related Articles, l

Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in spor Parkinson's disease and in dementia with Lewy bodies.
Brain Res. 1999 Oct 2;843(1-2):53-61.
PMID: 10528110 [PubMed - indexed for MEDLINE]

☐ **66:** Culvenor JG, McLean CA, Cutt S, Campbell BC, Maher F, Jakala P, Hartmann T, Beyreuther K, Masters CL, Li QX. Related Articles, l

Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.
Am J Pathol. 1999 Oct;155(4):1173-81.
PMID: 10514400 [PubMed - indexed for MEDLINE]

☐ **67:** Bayer TA, Jakala P, Hartmann T, Havas L, McLean C, Culvenor JG, Li QX, Masters CL, Falkai P, Beyreuther K. Related Articles, l

Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but in Alzheimer's disease beta-amyloid plaque cores.

Neurosci Lett. 1999 May 14;266(3):213-6.
PMID: 10465711 [PubMed - indexed for MEDLINE]

☐ **68:** Paik SR, Shin HJ, Lee JH, Chang CS, Kim J. Related Articles, l

Copper(II)-induced self-oligomerization of alpha-synuclein.
Biochem J. 1999 Jun 15;340 (Pt 3):821-8.
PMID: 10359669 [PubMed - indexed for MEDLINE]

☐ **69:** Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H. Related Articles, l

Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy.
Acta Neuropathol (Berl). 1998 Nov;96(5):445-52.
PMID: 9829807 [PubMed - indexed for MEDLINE]

☐ **70:** Lee JH, Shin HJ, Chang CS, Paik SR. Related Articles, l

Comparisons of the NACP self-oligomerizations induce by Abeta25-35 in the presence of dicyclohexylcarbodiimide and N-(ethoxycarbonyl)-2-ethoxy-1,2-dihydroquinoline.
Neurochem Res. 1998 Nov;23(11):1427-34.
PMID: 9814554 [PubMed - indexed for MEDLINE]

☐ **71:** Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Sisk A, Masliah E. Related Articles, l

Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein Lewy body disease as revealed by proteinase K and for acid pretreatment.
Lab Invest. 1998 Sep;78(9):1169-77.
PMID: 9759660 [PubMed - indexed for MEDLINE]

☐ **72:** Hsu LJ, Mallory M, Xia Y, Veinbergs I, Hashimoto M, Yoshimoto M, Thal LJ, Saitoh T, Masliah E. Related Articles, l

Expression pattern of synucleins (non-Abeta componen Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development.
J Neurochem. 1998 Jul;71(1):338-44.

PMID: 9648883 [PubMed - indexed for MEDLINE]

☐ **73:** Ishimaru H, Ueda K, Takahashi A, Maruyama Y. Related Articles, I

Changes in presynaptic protein NACP/alpha-synuclein an ischemic gerbil hippocampus.
Brain Res. 1998 Mar 30;788(1-2):311-4.
PMID: 9555070 [PubMed - indexed for MEDLINE]

☐ **74:** Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H. Related Articles, I

NACP, a presynaptic protein, immunoreactivity in Lew bodies in Parkinson's disease.
Neurosci Lett. 1997 Dec 12;239(1):45-8.
PMID: 9547168 [PubMed - indexed for MEDLINE]

☐ **75:** Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E. Related Articles, I

Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders.
Am J Pathol. 1998 Feb;152(2):367-72.
PMID: 9466562 [PubMed - indexed for MEDLINE]

☐ **76:** Jensen PH, Hojrup P, Hager H, Nielsen MS, Jacobsen L, Olesen OF, Gliemann J, Jakes R. Related Articles, I

Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC.
Biochem J. 1997 Apr 15;323 (Pt 2):539-46.
PMID: 9163350 [PubMed - indexed for MEDLINE]

☐ **77:** Xia Y, Rohan de Silva HA, Rosi BL, Yamaoka LH, Rimmler JB, Pericak-Vance MA, Roses AD, Chen X, Masliah E, DeTeresa R, Iwai A, Sundsmo M, Thomas RG, Hofstetter CR, Gregory E, Hansen LA, Katzman R, Thal LJ, Saitoh T. Related Articles, I

Genetic studies in Alzheimer's disease with an NACP/alpha-synuclein polymorphism.
Ann Neurol. 1996 Aug;40(2):207-15.
PMID: 8773602 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

1: Biochem J. 1997 Apr 15;323 (Pt 2):539-46.

Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NA precursor that bind Abeta and NAC.

Jensen PH, Hojrup P, Hager H, Nielsen MS, Jacobsen Olesen OF, Gliemann J, Jakes R.

Department of Medical Biochemistry, University of Aarh Ole Worms Alle, Building 170, DK-8000 Aarhus C, Denmark.

NAC, a 35-residue peptide derived from the neuronal pro alpha-synuclein/NAC precursor, is tightly associated with Abeta fibrils in Alzheimer's disease amyloid, and alpha-synuclein has recently been shown to bind Abeta in vitro. have studied the interaction between Abeta and synuclein aiming at determining segments in alpha-synuclein that ca account for the binding, as well as identifying a possible interaction between Abeta and the beta-type synuclein. W report that Abeta binds to native and recombinant alpha-synuclein, and to beta-synuclein in an SDS-sensitive interaction (IC50 approx. 20 microM), as determined by chemical cross-linking and solid-phase binding assays. alp Synuclein and beta-synuclein were found to stimulate Abe aggregation in vitro to the same extent. The synucleins als

displayed Abeta-inhibitable binding of NAC and they wei capable of forming dimers. Using proteolytic fragmentati of alpha-synuclein and cross-linking to 125I-Abeta, we identified two consecutive binding domains (residues 1-5(and 57-97) by Edman degradation and mass spectrometri(analysis, and a synthetic peptide comprising residues 32-5 possessed Abeta-binding activity. To test further the possi significance in pathology, alpha-synuclein was biotinylate and shown to bind specifically to amyloid plaques in a br; with Alzheimer's disease. It is proposed that the multiple Abeta-binding sites in alpha-synuclein are involved in the development of amyloid plaques.

PMID: 9163350 [PubMed - indexed for MEDLINE]

1: Eur J Biochem. 2000 Apr;267(8):2186-94. Related Articles,

Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments ther correlates to formation of beta-sheet structure a fibrils.

Bodles AM, Guthrie DJ, Harriott P, Campbell P, Irvin GB.

Centre for Peptide and Protein Engineering, School of Biology and Biochemistry, The Queen's University of Belfast, Northern Ireland.

The non-Abeta component of Alzheimer's disease amyloi (NAC) and its precursor alpha-synuclein have been linkec amyloidogenesis in Alzheimer's disease (AD), Parkinson' disease (PD) and dementia with Lewy bodies (DLB). Previously we have shown that NAC forms beta-sheet structures and fibrils [El-Agnaf, O.M.A., Bodles, A.M., Guthrie, D.J.S., Harriott, P. & Irvine, G.B. (1998) Eur. J. Biochem. 258, 157-163]. As a measure of their neurotoxi potential we have examined the ability of fresh and aged NAC and fragments thereof to inhibit the reduction of the redox dye 3-(4, 5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide by rat pheochromocytoma P cells. Micromolar concentrations of NAC and fragments

thereof display varying degrees of toxicity. On immediate dissolution and after an incubation period for 3 days at 37 degrees C the full-length peptide and fragments NAC(3-1 and NAC(1-18) scrambled sequence [NAC(1-18 s)] were toxic, whereas fragments NAC(1-13) and NAC(6-14) wer not. CD indicates that NAC(3-18) and NAC(1-18 s) exhit beta-sheet secondary structure in aqueous solution, where NAC(1-13) and NAC(6-14) do not. NAC(3-18) aggregate as indicated by concentration of peptide remaining in solu after 3 days measured by an HPLC assay, and forms fibril as determined by electron microscopy. However, althougl some fibrils were detected for NAC(1-18 s) it does not co out of solution to a significant degree. Fragments NAC(1- and NAC(6-14) form few fibrils and remain in solution. These findings indicate that the ability of the central regio NAC to form beta-sheet secondary structures is important determining the toxicity of the peptide. This contrasts witl what has been reported previously for most Abeta peptide their toxicity appears to require the peptide to have forme fibrillary aggregates as well as displaying beta-sheet. The results suggest that an intermediate, which exhibits beta-s structure, may be responsible for the toxic properties of N and provides further evidence for the role of NAC in the pathogenesis of AD, PD and DLB.

PMID: 10759841 [PubMed - indexed for MEDLINE]

1: J Alzheimers Dis. 2003 Apr;5(2):139-48. Related Articles, IOS Press Full Text

Alpha-synuclein aggregation and neurodegenerative diseases.

Ma QL, Chan P, Yoshii M, Ueda K.

Department of Neural Plasticity, Tokyo Institute of Psychiatry, Tokyo 156-8585, Japan.

Alpha-synuclein is a neuronal protein originally identifiec Alzheimer's disease (AD) amyloid plaques in 1993 and named non-Abeta component precursor (NACP) [92]. Lat the discovery of two missense mutations (G88C and G20 which resulted in Ala30Pro (A30P) and Ala53Thr (A53T substitutions, of the alpha-synuclein gene in certain autosomal-dominant early onset familial Parkinson's dise (PD) has greatly promoted the understanding of the role o alpha-synuclein in the pathogenesis of neurodegenerative diseases, such as PD, dementia with Lewy bodies (DLB) multiple system atrophy (MSA) [5,6,51,75]. At present, it widely accepted that alpha-synuclein may play a central r in several neurodegenerative disorders because of the presence of insoluble alpha-synuclein as the major fibrilla component of inclusion bodies. From the cloning of the human alpha-synuclein cDNA in 1993 to the present, alpl synuclein has been carefully documented in many aspects this article, we review the progress of studies on alpha-

synuclein and its role in alpha-synuclein-related neurodegenerative diseases.

Publication Types:
- Review
- Review, Tutorial

PMID: 12719631 [PubMed - indexed for MEDLINE]

NCBI PubMed National Library of Medicine NLM [Sign In]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journal

Search PubMed for Parkinsons AND immunization Go Clear Sav

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals
Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)
Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

All: 8 Review: 2

Items 1 - 8 of 8 One p

1: Sanftner LM, Suzuki BM, Doroudchi MM, Feng L, McClelland A, Forsayeth JR, Cunningham J. Related Articles, l

Striatal delivery of rAAV-hAADC to rats with preexistir immunity to AAV.
Mol Ther. 2004 Mar;9(3):403-9.
PMID: 15006607 [PubMed - indexed for MEDLINE]

2: Riess O, Berg D, Kruger R, Schulz JB. Related Articles, l

Therapeutic strategies for Parkinson's disease based on d derived from genetic research.
J Neurol. 2003 Feb;250 Suppl 1:I3-10. Review.
PMID: 12761628 [PubMed - indexed for MEDLINE]

3: Bakay RA, Boyer KL, Freed CR, Ansari AA. Related Articles, l

Immunological responses to injury and grafting in the central nervous system of nonhuman primates.
Cell Transplant. 1998 Mar-Apr;7(2):109-20.
PMID: 9588593 [PubMed - indexed for MEDLINE]

4: Zlokovic BV, Apuzzo ML. Related Articles, l

Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous system
Neurosurgery. 1997 Apr;40(4):789-803; discussion 803-4. Revie
PMID: 9092853 [PubMed - indexed for MEDLINE]

5: Kryzhanovskii GN, Man'kovskii NB, Karaban' IN, Magaeva SV, Trekova NA, Vetrile LA, Basharova LA, Atadzhanov MA, Golubev KM. Related Articles, l

[Serotonin antibodies and their possible role in parkinsonism]
Zh Nevropatol Psikhiatr Im S S Korsakova. 1994;94(5):21-6. Russian.
PMID: 7900444 [PubMed - indexed for MEDLINE]

6: Persiani S, Pianezzola E, Broutin F, Fonte G, Strolin Benedetti M. Related Articles, l

Radioimmunoassay for the synthetic ergoline derivative cabergoline in biological fluids.
J Immunoassay. 1992;13(3):457-76.
PMID: 1354673 [PubMed - indexed for MEDLINE]

7: Hirsch E, Ruberg M, Dardenne M, Portier MM, Javoy-Agid F, Bach JF, Agid Y. Related Articles, l

Monoclonal antibodies raised against Lewy bodies in bra from subjects with Parkinson's disease.
Brain Res. 1985 Oct 21;345(2):374-8.
PMID: 2994847 [PubMed - indexed for MEDLINE]

8: [No authors listed] Related Articles, l

[Usefulness of new drugs]
MMW Munch Med Wochenschr. 1980 Jan 4;122(1):28-9. Germa
No abstract available.
PMID: 6767916 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

1: Brain Res. 1985 Oct 21;345(2):374-8. Related Articles,

Monoclonal antibodies raised against Lewy bodi in brains from subjects with Parkinson's disease

Hirsch E, Ruberg M, Dardenne M, Portier MM, Javoy Agid F, Bach JF, Agid Y.

Monoclonal antibodies which immunocytochemically lab Lewy bodies on sections of substantia nigra from subjects with Parkinson's disease were produced by immunization mice with substantia nigra and locus coeruleus containing Lewy bodies from parkinsonian subjects post-mortem. Te of specificity indicate that the antibodies do not recognize same antigen. One of the antibodies (G7) immunocytochemically labels only Lewy bodies, the othe (G9) also faintly labels the cell bodies of nigral dopamine neurons and cerebellar Purkinje cells in both normal and parkinsonian brains. Absorption experiments show, howe that the G7 antigen is present in normal substantia nigra a the G9 antigen in normal substantia nigra and Purkinje ce Neither of the antibodies seems to be directed against neurofilament protein. Immunoblots after two-directional electrophoresis indicate that antibody G7 labels a protein an iso-electric point around 5.6 and a mol. wt. of approximately 40 kdalton, whereas the protein labeled by antibody G9 has an iso-electric point of near 8 and a mol. above 70 kdalton.

Monoclonal antibodies raised against Lewy bodi in brains from subjects with Parkinson's disease

Hirsch E, Ruberg M, Dardenne M, Portier MM, Javoy Agid F, Bach JF, Agid Y.

Monoclonal antibodies which immunocytochemically lab Lewy bodies on sections of substantia nigra from subjects with Parkinson's disease were produced by immunization mice with substantia nigra and locus coeruleus containing Lewy bodies from parkinsonian subjects post-mortem. Te of specificity indicate that the antibodies do not recognize same antigen. One of the antibodies (G7) immunocytochemically labels only Lewy bodies, the othe (G9) also faintly labels the cell bodies of nigral dopamine neurons and cerebellar Purkinje cells in both normal and parkinsonian brains. Absorption experiments show, howe that the G7 antigen is present in normal substantia nigra a the G9 antigen in normal substantia nigra and Purkinje ce Neither of the antibodies seems to be directed against neurofilament protein. Immunoblots after two-directional electrophoresis indicate that antibody G7 labels a protein an iso-electric point around 5.6 and a mol. wt. of approximately 40 kdalton, whereas the protein labeled by antibody G9 has an iso-electric point of near 8 and a mol. above 70 kdalton.

NCBI PubMed National Library of Medicine NLM [Sign In]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journal

Search PubMed for Parkinsons AND antibody AND therapy Go Clear Sav

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals
Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)
Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

All: 58 Review: 11

Items 1 - 58 of 58 One p

1: Zhang Y, Schlachetzki F, Zhang YF, Boado RJ, Pardridge WM. Related Articles, l

Normalization of striatal tyrosine hydroxylase and revers of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter.
Hum Gene Ther. 2004 Apr;15(4):339-50.
PMID: 15053859 [PubMed - indexed for MEDLINE]

2: Komel'kova LV, Vitreshchak TV, Zhirnova IG, Poleshchuk VV, Stvolinskii SL, Mikhailov VV, Gannushkina IV, Piradov MA. Related Articles, l

[Biochemical and immunological induces of the blood in Parkinson's disease and their correction with the help of laser therapy]
Patol Fiziol Eksp Ter. 2004 Jan-Mar;(1):15-8. Russian.
PMID: 15052871 [PubMed - indexed for MEDLINE]

3: Sanftner LM, Suzuki BM, Doroudchi MM, Feng L, McClelland A, Forsayeth JR, Cunningham J. Related Articles, l

Striatal delivery of rAAV-hAADC to rats with preexistir immunity to AAV.
Mol Ther. 2004 Mar;9(3):403-9.
PMID: 15006607 [PubMed - indexed for MEDLINE]

4: Marchionini DM, Collier TJ, Camargo M, McGuire S, Pitzer M, Sortwell CE. Related Articles, l

Interference with anoikis-induced cell death of dopamine neurons: implications for augmenting embryonic graft survival in a rat model of Parkinson's disease.

J Comp Neurol. 2003 Sep 15;464(2):172-9.
PMID: 12898610 [PubMed - indexed for MEDLINE]

☐ **5:** Ren Y, Zhao J, Feng J. Related Articles, l

Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation.
J Neurosci. 2003 Apr 15;23(8):3316-24.
PMID: 12716939 [PubMed - indexed for MEDLINE]

☐ **6:** Lopez-Real A, Rodriguez-Pallares J, Guerra MJ, Labandeira-Garcia JL. Related Articles, l

Localization and functional significance of striatal neuro immunoreactive to aromatic L-amino acid decarboxylase tyrosine hydroxylase in rat Parkinsonian models.
Brain Res. 2003 Apr 18;969(1-2):135-46.
PMID: 12676374 [PubMed - indexed for MEDLINE]

☐ **7:** Becker G. Related Articles, l

[Methods for the early diagnosis of Parkinson's disease]
Nervenarzt. 2003 Mar;74 Suppl 1:S7-11. German.
PMID: 12624678 [PubMed - indexed for MEDLINE]

☐ **8:** Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Related Articles, l

Intravenous nonviral gene therapy causes normalization striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism.
Hum Gene Ther. 2003 Jan 1;14(1):1-12.
PMID: 12573054 [PubMed - indexed for MEDLINE]

☐ **9:** Hurtado-Lorenzo A, David A, Thomas C, Castro MG, Lowenstein PR. Related Articles, l

Use of recombinant adenovirus for gene transfer into the brain. Evaluation of gene transfer efficiency, toxicity, an inflammatory and immune reactions.
Methods Mol Med. 2003;76:113-33. No abstract available.
PMID: 12526161 [PubMed - indexed for MEDLINE]

☐ **10:** Garcia-Moreno JM, Chacon J. Related Articles, l

[Hypothyroidism concealed by Parkinson's disease]
Rev Neurol. 2002 Oct 16-31;35(8):741-2. Spanish.
PMID: 12402227 [PubMed - indexed for MEDLINE]

☐ **11:** Czlonkowska A, Kurkowska-Jastrzebska I, Czlonkowski A, Peter D, Stefano GB. Related Articles, I

Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide.
Med Sci Monit. 2002 Aug;8(8):RA165-77. Review.
PMID: 12165754 [PubMed - indexed for MEDLINE]

☐ **12:** Wu C, Liu Y, Wang J, Yang Y, Jiang Y. Related Articles, I

[Intracerebral transplantation of nerve cells and genetic modified cells for disorders of central nervous system, a basic and clinical study]
Zhonghua Yi Xue Za Zhi. 2002 Apr 10;82(7):440-4. Chinese.
PMID: 12133510 [PubMed - indexed for MEDLINE]

☐ **13:** Nagatsu T. Related Articles, I

Parkinson's disease: changes in apoptosis-related factor suggesting possible gene therapy.
J Neural Transm. 2002 May;109(5-6):731-45. Review.
PMID: 12111464 [PubMed - indexed for MEDLINE]

☐ **14:** Clarke DJ, Branton RL. Related Articles, I

A role for tumor necrosis factor alpha in death of dopaminergic neurons following neural transplantation.
Exp Neurol. 2002 Jul;176(1):154-62.
PMID: 12093092 [PubMed - indexed for MEDLINE]

☐ **15:** Palfi S, Leventhal L, Chu Y, Ma SY, Emborg M, Bakay R, Deglon N, Hantraye P, Aebischer P, Kordower JH. Related Articles, I

Lentivirally delivered glial cell line-derived neurotroph factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration
J Neurosci. 2002 Jun 15;22(12):4942-54.
PMID: 12077191 [PubMed - indexed for MEDLINE]

☐ **16:** Jones IW, Bolam JP, Wonnacott S. Related Articles, I

Presynaptic localisation of the nicotinic acetylcholine receptor beta2 subunit immunoreactivity in rat nigrostri dopaminergic neurones.
J Comp Neurol. 2001 Oct 15;439(2):235-47.
PMID: 11596051 [PubMed - indexed for MEDLINE]

☐ **17:** Pierantozzi M, Pietroiusti A, Sancesario G, Lunardi G, Fedele E, Giacomini P, Frasca S, Galante A, Marciani MG, Stanzione P. Related Articles, l

Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients.
Neurol Sci. 2001 Feb;22(1):89-91.
PMID: 11487216 [PubMed - indexed for MEDLINE]

☐ **18:** Brevig T, Meyer M, Kristensen T, Zimmer J, Holgersson J. Related Articles, l

Xenotransplantation for brain repair: reduction of porci donor tissue immunogenicity by treatment with anti-Ga antibodies and complement.
Transplantation. 2001 Jul 27;72(2):190-6.
PMID: 11477337 [PubMed - indexed for MEDLINE]

☐ **19:** Larsson LC, Widner H. Related Articles, l

Neural tissue xenografting.
Scand J Immunol. 2000 Sep;52(3):249-56. Review.
PMID: 10972900 [PubMed - indexed for MEDLINE]

☐ **20:** Dobbs RJ, Charlett A, Dobbs SM, Weller C, Peterson DW. Related Articles, l

Parkinsonism: differential age-trend in Helicobacter pyl antibody.
Aliment Pharmacol Ther. 2000 Sep;14(9):1199-205.
PMID: 10971237 [PubMed - indexed for MEDLINE]

☐ **21:** Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, Fischman AJ, Thomas C, Feldman RG, Kassissieh S, Raineri R, Manhart C, Penney D, Fink JS, Isacson O. Related Articles, l

Transplantation of embryonic porcine mesencephalic tissue in patients with PD.
Neurology. 2000 Mar 14;54(5):1042-50.
PMID: 10720272 [PubMed - indexed for MEDLINE]

☐ **22:** Sumitran S, Anderson P, Widner H, Holgersson J. Related Articles, l

Porcine embryonic brain cell cytotoxicity mediated by

human natural killer cells.
Cell Transplant. 1999 Nov-Dec;8(6):601-10.
PMID: 10701489 [PubMed - indexed for MEDLINE]

☐ **23:** Hashimoto S, Sawada T, Inoue T, Yamamoto K, Iwata M. Related Articles, I

Cholinergic-drug induced sicca syndrome in Parkinson' disease: a case report and a review of the literature.
Clin Neurol Neurosurg. 1999 Dec;101(4):268-70. Review.
PMID: 10622459 [PubMed - indexed for MEDLINE]

☐ **24:** Kroll RA, Neuwelt EA. Related Articles, I

Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means.
Neurosurgery. 1998 May;42(5):1083-99; discussion 1099-100. Review.
PMID: 9588554 [PubMed - indexed for MEDLINE]

☐ **25:** Fink JS. Related Articles, I

Transplantation in Parkinson's disease.
Artif Organs. 1997 Nov;21(11):1199-202. Review.
PMID: 9384326 [PubMed - indexed for MEDLINE]

☐ **26:** Kordower JH, Styren S, Clarke M, DeKosky ST, Olanow CW, Freeman TB. Related Articles, I

Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants.
Cell Transplant. 1997 May-Jun;6(3):213-9.
PMID: 9171154 [PubMed - indexed for MEDLINE]

☐ **27:** Zlokovic BV, Apuzzo ML. Related Articles, I

Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous syste
Neurosurgery. 1997 Apr;40(4):789-803; discussion 803-4. Revi
PMID: 9092853 [PubMed - indexed for MEDLINE]

☐ **28:** Borlongan CV, Stahl CE, Cameron DF, Saporta S, Freeman TB, Cahill DW, Sanberg PR. Related Articles, I

CNS immunological modulation of neural graft rejectio

and survival.
Neurol Res. 1996 Aug;18(4):297-304. Review.
PMID: 8875445 [PubMed - indexed for MEDLINE]

☐ **29:** Schneider JS, Roeltgen DP, Rothblat DS, Chapas-Crilly J, Seraydarian L, Rao J. Related Articles, I

GM1 ganglioside treatment of Parkinson's disease: an o pilot study of safety and efficacy.
Neurology. 1995 Jun;45(6):1149-54.
PMID: 7783880 [PubMed - indexed for MEDLINE]

☐ **30:** Ansari AA, Mayne A, Freed CR, Breeze RE, Schneck SA, O'Brien CF, Kriek EH, Zhang YB, Mazziotta JC, Hutchinson M, et al. Related Articles, I

Lack of a detectable systemic humoral/cellular allogene response in human and nonhuman primate recipients of embryonic mesencephalic allografts for the therapy of Parkinson's disease.
Transplant Proc. 1995 Feb;27(1):1401-5. No abstract available.
PMID: 7878926 [PubMed - indexed for MEDLINE]

☐ **31:** Lorigados L, Molina H, Serrano T, Pavon N, Robinson MA, Alvarez L, Soderstrom S, Ebendal T. Related Articles, I

Evolutive levels of NGF in neurodegenerative disorders
Mol Chem Neuropathol. 1995 Feb-Apr;24(2-3):231-4. No abstı available.
PMID: 7632325 [PubMed - indexed for MEDLINE]

☐ **32:** Nakao N, Itakura T, Uematsu Y, Nakai M, Komai N, Furukawa S. Related Articles, I

Pretreatment with interleukin-1 enhances survival of sympathetic ganglionic neuron grafts.
Neurol Med Chir (Tokyo). 1994 Jul;34(7):407-11.
PMID: 7526227 [PubMed - indexed for MEDLINE]

☐ **33:** Kryzhanovskii GN, Man'kovskii NB, Karaban' IN, Magaeva SV, Trekova NA, Vetrile LA, Basharova LA, Atadzhanov MA, Golubev KM. Related Articles, I

[Serotonin antibodies and their possible role in parkinsonism]
Zh Nevropatol Psikhiatr Im S S Korsakova. 1994;94(5):21-6.

Russian.
PMID: 7900444 [PubMed - indexed for MEDLINE]

☐ **34:** Visser LH, Koudstaal PJ, van de Merwe JP. Related Articles, l

Hemiparkinsonism in a patient with primary Sjogren's syndrome. A case report and a review of the literature.
Clin Neurol Neurosurg. 1993 Jun;95(2):141-5.
PMID: 8344013 [PubMed - indexed for MEDLINE]

☐ **35:** Bowsher RR, Apathy JM, Compton JA, Wolen RL, Carlson KH, DeSante KA. Related Articles, l

Sensitive, specific radioimmunoassay for quantifying pergolide in plasma.
Clin Chem. 1992 Oct;38(10):1975-80.
PMID: 1394981 [PubMed - indexed for MEDLINE]

☐ **36:** Nagao T, Takagi K, Hashida H, Masaki T, Sakuta M. Related Articles, l

[A case of progressive systemic sclerosis and Sjogren's syndrome complicated by parkinsonism with special reference to the beneficial effect of corticosteroid]
Rinsho Shinkeigaku. 1991 Nov;31(11):1238-40. Japanese.
PMID: 1813195 [PubMed - indexed for MEDLINE]

☐ **37:** Fiszer U, Piotrowska K, Korlak J, Czlonkowska A. Related Articles, l

The immunological status in Parkinson's disease.
Med Lab Sci. 1991 Jul;48(3):196-200.
PMID: 1787777 [PubMed - indexed for MEDLINE]

☐ **38:** Carvey PM, McRae A, Lint TF, Ptak LR, Lo ES, Goetz CG, Klawans HL. Related Articles, l

The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic marke in Parkinson's disease.
Neurology. 1991 May;41(5 Suppl 2):53-8; discussion 59-60. Review.
PMID: 2041594 [PubMed - indexed for MEDLINE]

☐ **39:** Rahamim E, Kahane A, Sharon R. Related Articles, l

Electron microscopy of red blood cells altered by auto-immunity-inducing drugs.
Vox Sang. 1990;58(4):292-9.

PMID: 2399695 [PubMed - indexed for MEDLINE]

☐ **40:** Carvey PM, McRae A, Ptak LR, Kao LC, Lo ES, Goetz CG, Tanner CM, Penn RD, Klawans HL. Related Articles, I

Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship striatal-derived DA neuron trophic factor.
Prog Brain Res. 1990;82:693-7. No abstract available.
PMID: 2290972 [PubMed - indexed for MEDLINE]

☐ **41:** Ahlskog JE, Tyce GM, Kelly PJ, van Heerden JA, Stoddard SL, Carmichael SW. Related Articles, I

Cerebrospinal fluid indices of blood-brain barrier permeability following adrenal-brain transplantation in patients with Parkinson's disease.
Exp Neurol. 1989 Aug;105(2):152-61.
PMID: 2753115 [PubMed - indexed for MEDLINE]

☐ **42:** Uchida K, Kohsaka S. Related Articles, I

[Current advances in neural transplantation]
Hum Cell. 1989 Jun;2(2):150-5. Japanese.
PMID: 2577249 [PubMed - indexed for MEDLINE]

☐ **43:** McRae-Degueurce A, Klawans HL, Penn RD, Dahlstrom A, Tanner CM, Goetz CG, Carvey PM. Related Articles, I

An antibody in the CSF of Parkinson's disease patients disappears following adrenal medulla transplantation.
Neurosci Lett. 1988 Nov 22;94(1-2):192-7.
PMID: 3241668 [PubMed - indexed for MEDLINE]

☐ **44:** Brundin P, Strecker RE, Widner H, Clarke DJ, Nilsson OG, Astedt B, Lindvall O, Bjorklund A. Related Articles, I

Human fetal dopamine neurons grafted in a rat model o Parkinson's disease: immunological aspects, spontaneo and drug-induced behaviour, and dopamine release.
Exp Brain Res. 1988;70(1):192-208.
PMID: 3402564 [PubMed - indexed for MEDLINE]

☐ **45:** Ueno S, Takahashi M, Kajiyama K, Okahisa N, Hazama T, Yorifuji S, Tarui S. Related Articles, I

Parkinson's disease and myasthenia gravis: adverse effe of trihexyphenidyl on neuromuscular transmission.
Neurology. 1987 May;37(5):832-3.
PMID: 3033545 [PubMed - indexed for MEDLINE]

☐ **46:** Riederer P, Konradi C, Schay V, Kienzl E, Birkmayer G, Danielczyk W, Sofic E, Youdim MB. Related Articles, l

Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprer
Adv Neurol. 1987;45:111-8.
PMID: 3030067 [PubMed - indexed for MEDLINE]

☐ **47:** Brundin P, Nilsson OG, Strecker RE, Lindvall O, Astedt B, Bjorklund A. Related Articles, l

Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease.
Exp Brain Res. 1986;65(1):235-40.
PMID: 3542544 [PubMed - indexed for MEDLINE]

☐ **48:** Pletscher A. Related Articles, l

[Research--the source of medical progress]
Hautarzt. 1985;36 Suppl 7:1-5. German. No abstract available.
PMID: 3842698 [PubMed - indexed for MEDLINE]

☐ **49:** Pouplard A, Emile J. Related Articles, l

Autoimmunity in Parkinson's disease.
Adv Neurol. 1984;40:307-13. No abstract available.
PMID: 6695608 [PubMed - indexed for MEDLINE]

☐ **50:** Elizan TS, Casals J. Related Articles, l

The viral hypothesis in parkinsonism.
J Neural Transm Suppl. 1983;19:75-88.
PMID: 6583315 [PubMed - indexed for MEDLINE]

☐ **51:** Marais C. Related Articles, l

[Duality of dopaminergic receptors. Pharmacologic and clinical perspectives]
Sem Hop. 1978 May;54(13-16):563-7. Review. French.
PMID: 211603 [PubMed - indexed for MEDLINE]

☐ **52:** Linstrom FD, Lieden G, Enstrom MS. Related Articles, l

Dose-related levodopa-induced haemolytic anaemia.

Ann Intern Med. 1977 Mar;86(3):298-300.
PMID: 402877 [PubMed - indexed for MEDLINE]

☐ **53:** Territo MC, Peters RW, Tanaka KR. Related Articles, l

Autoimmune hemolytic anemia due to levodopa therap
JAMA. 1973 Dec 10;226(11):1347-8. No abstract available.
PMID: 4202390 [PubMed - indexed for MEDLINE]

☐ **54:** Goldberg LS, Bluestone R. Related Articles, l

Studies on serologic abnormalities induced by L-dopa.
Vox Sang. 1973 Feb;24(2):171-4. No abstract available.
PMID: 4539455 [PubMed - indexed for MEDLINE]

☐ **55:** Boyd AE 3rd, Lebovitz HE, Feldman JM. Related Articles, l

Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-Dop
J Clin Endocrinol Metab. 1971 Nov;33(5):829-37. No abstract available.
PMID: 5125386 [PubMed - indexed for MEDLINE]

☐ **56:** Henry RE, Goldberg LS, Sturgeon P, Ansel RD. Related Articles, l

Serologic abnormalities associated with L-dopa therapy
Vox Sang. 1971 Apr;20(4):306-16. No abstract available.
PMID: 4999317 [PubMed - indexed for MEDLINE]

☐ **57:** Nagay B. Related Articles, l

[Dupuytren's contracture]
Wiad Lek. 1970 Nov 15;23(22):1979-83. Review. Polish. No abstract available.
PMID: 4922139 [PubMed - indexed for MEDLINE]

☐ **58:** Cotzias GC, Papavasiliou PS. Related Articles, l

Autoimmunity in patients treated with levodopa.
JAMA. 1969 Feb 17;207(7):1353-4. No abstract available.
PMID: 5304532 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

NCBI PubMed National Library of Medicine NLM [Sign In]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journal

Search PubMed for Lewy Body AND antibody AND therapy Go Clear Sav

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals
Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

All: 1 Review: 0

1: Zhou C, Emadi S, Sierks MR, Messer A. Related Articles, l

A human single-chain Fv intrabody blocks aberrant cellu effects of overexpressed alpha-synuclein.
Mol Ther. 2004 Dec;10(6):1023-31.
PMID: 15564134 [PubMed - in process]

NCBI PubMed National Library of Medicine NLM [Sign In]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journal

Search PubMed for Lewy Body AND antibody AND treatment Go Clear Sav

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

All: 7 Review: 0

Text Version

Items 1 - 7 of 7 One p

Entrez PubMed

1: Zhou C, Emadi S, Sierks MR, Messer A. Related Articles, l

A human single-chain Fv intrabody blocks aberrant cellu effects of overexpressed alpha-synuclein.
Mol Ther. 2004 Dec;10(6):1023-31.
PMID: 15564134 [PubMed - in process]

2: Hartmann A, Michel PP, Troadec JD, Mouatt-Prigent A, Faucheux BA, Ruberg M, Agid Y, Hirsch EC. Related Articles, l

Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
J Neurochem. 2001 Mar;76(6):1785-93.
PMID: 11259496 [PubMed - indexed for MEDLINE]

3: Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Sisk A, Masliah E. Related Articles, l

Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein i Lewy body disease as revealed by proteinase K and form acid pretreatment.
Lab Invest. 1998 Sep;78(9):1169-77.
PMID: 9759660 [PubMed - indexed for MEDLINE]

4: Singer SM, Chambers CB, Newfry GA, Norlund MA, Muma NA. Related Articles, l

Tau in aluminum-induced neurofibrillary tangles.
Neurotoxicology. 1997;18(1):63-76.
PMID: 9215989 [PubMed - indexed for MEDLINE]

5: Muma NA, Singer SM. Related Articles, l

Aluminum-induced neuropathology: transient changes in

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

microtubule-associated proteins.
Neurotoxicol Teratol. 1996 Nov-Dec;18(6):679-90.
PMID: 8947945 [PubMed - indexed for MEDLINE]

☐ **6:** Masaki T, Ishiura S, Sugita H, Kwak S. Related Articles, I

Multicatalytic proteinase is associated with characteristic oval structures in cortical Lewy bodies: an immunocytochemical study with light and electron microscopy.
J Neurol Sci. 1994 Apr;122(2):127-34.
PMID: 8021694 [PubMed - indexed for MEDLINE]

☐ **7:** Bancher C, Lassmann H, Budka H, Jellinger K, Grundke-Iqbal I, Iqbal K, Wiche G, Seitelberger F, Wisniewski HM. Related Articles, I

An antigenic profile of Lewy bodies: immunocytochemi indication for protein phosphorylation and ubiquitination
J Neuropathol Exp Neurol. 1989 Jan;48(1):81-93.
PMID: 2462024 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

NCBI PubMed National Library of Medicine NLM [Sign In]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journal

Search PubMed for Parkinsons AND antibody AND treatment Go Clear Sav

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

All: 70 Review: 11

Text Version

Items 1 - 70 of 70 One p

Entrez PubMed

1: Zhang Y, Schlachetzki F, Zhang YF, Boado RJ, Pardridge WM. Related Articles, l

Normalization of striatal tyrosine hydroxylase and revers of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter.
Hum Gene Ther. 2004 Apr;15(4):339-50.
PMID: 15053859 [PubMed - indexed for MEDLINE]

2: Komel'kova LV, Vitreshchak TV, Zhirnova IG, Poleshchuk VV, Stvolinskii SL, Mikhailov VV, Gannushkina IV, Piradov MA. Related Articles, l

[Biochemical and immunological induces of the blood in Parkinson's disease and their correction with the help of laser therapy]
Patol Fiziol Eksp Ter. 2004 Jan-Mar;(1):15-8. Russian.
PMID: 15052871 [PubMed - indexed for MEDLINE]

3: Sanftner LM, Suzuki BM, Doroudchi MM, Feng L, McClelland A, Forsayeth JR, Cunningham J. Related Articles, l

Striatal delivery of rAAV-hAADC to rats with preexistir immunity to AAV.
Mol Ther. 2004 Mar;9(3):403-9.
PMID: 15006607 [PubMed - indexed for MEDLINE]

4: Shang T, Kotamraju S, Kalivendi SV, Hillard CJ, Kalyanaraman B. Related Articles, l

1-Methyl-4-phenylpyridinium-induced apoptosis in cerebellar granule neurons is mediated by transferrin receptor iron-dependent depletion of tetrahydrobiopterin

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut

My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

and neuronal nitric-oxide synthase-derived superoxide.
J Biol Chem. 2004 Apr 30;279(18):19099-112. Epub 2004 Jan 2
PMID: 14752097 [PubMed - indexed for MEDLINE]

☐ **5:** Wiley RG, Harrison MB, Levey AI, Lappi DA. Related Articles, I

Destruction of midbrain dopaminergic neurons by using immunotoxin to dopamine transporter.
Cell Mol Neurobiol. 2003 Oct;23(4-5):839-50.
PMID: 14514035 [PubMed - indexed for MEDLINE]

☐ **6:** Marchionini DM, Collier TJ, Camargo M, McGuire S, Pitzer M, Sortwell CE. Related Articles, I

Interference with anoikis-induced cell death of dopamine neurons: implications for augmenting embryonic graft survival in a rat model of Parkinson's disease.
J Comp Neurol. 2003 Sep 15;464(2):172-9.
PMID: 12898610 [PubMed - indexed for MEDLINE]

☐ **7:** Ren Y, Zhao J, Feng J. Related Articles, I

Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation.
J Neurosci. 2003 Apr 15;23(8):3316-24.
PMID: 12716939 [PubMed - indexed for MEDLINE]

☐ **8:** Lopez-Real A, Rodriguez-Pallares J, Guerra MJ, Labandeira-Garcia JL. Related Articles, I

Localization and functional significance of striatal neuro immunoreactive to aromatic L-amino acid decarboxylase tyrosine hydroxylase in rat Parkinsonian models.
Brain Res. 2003 Apr 18;969(1-2):135-46.
PMID: 12676374 [PubMed - indexed for MEDLINE]

☐ **9:** Becker G. Related Articles, I

[Methods for the early diagnosis of Parkinson's disease]
Nervenarzt. 2003 Mar;74 Suppl 1:S7-11. German.
PMID: 12624678 [PubMed - indexed for MEDLINE]

☐ **10:** Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Related Articles, I

Intravenous nonviral gene therapy causes normalization striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism.

Hum Gene Ther. 2003 Jan 1;14(1):1-12.
PMID: 12573054 [PubMed - indexed for MEDLINE]

☐ **11:** Hurtado-Lorenzo A, David A, Thomas C, Castro MG, Lowenstein PR. Related Articles, l

Use of recombinant adenovirus for gene transfer into th rat brain. Evaluation of gene transfer efficiency, toxicity and inflammatory and immune reactions.
Methods Mol Med. 2003;76:113-33. No abstract available.
PMID: 12526161 [PubMed - indexed for MEDLINE]

☐ **12:** Kalivendi SV, Kotamraju S, Cunningham S, Shang T, Hillard CJ, Kalyanaraman B. Related Articles, l

1-Methyl-4-phenylpyridinium (MPP+)-induced apoptos and mitochondrial oxidant generation: role of transferri receptor-dependent iron and hydrogen peroxide.
Biochem J. 2003 Apr 1;371(Pt 1):151-64.
PMID: 12523938 [PubMed - indexed for MEDLINE]

☐ **13:** Garcia-Moreno JM, Chacon J. Related Articles, l

[Hypothyroidism concealed by Parkinson's disease]
Rev Neurol. 2002 Oct 16-31;35(8):741-2. Spanish.
PMID: 12402227 [PubMed - indexed for MEDLINE]

☐ **14:** Czlonkowska A, Kurkowska-Jastrzebska I, Czlonkowski A, Peter D, Stefano GB. Related Articles, l

Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide.
Med Sci Monit. 2002 Aug;8(8):RA165-77. Review.
PMID: 12165754 [PubMed - indexed for MEDLINE]

☐ **15:** Wu C, Liu Y, Wang J, Yang Y, Jiang Y. Related Articles, l

[Intracerebral transplantation of nerve cells and genetic modified cells for disorders of central nervous system, a basic and clinical study]
Zhonghua Yi Xue Za Zhi. 2002 Apr 10;82(7):440-4. Chinese.
PMID: 12133510 [PubMed - indexed for MEDLINE]

☐ **16:** Nagatsu T. Related Articles, l

Parkinson's disease: changes in apoptosis-related factor suggesting possible gene therapy.
J Neural Transm. 2002 May;109(5-6):731-45. Review.

PMID: 12111464 [PubMed - indexed for MEDLINE]

☐ **17:** Clarke DJ, Branton RL. Related Articles, l

A role for tumor necrosis factor alpha in death of dopaminergic neurons following neural transplantation.
Exp Neurol. 2002 Jul;176(1):154-62.
PMID: 12093092 [PubMed - indexed for MEDLINE]

☐ **18:** Palfi S, Leventhal L, Chu Y, Ma SY, Emborg M, Bakay R, Deglon N, Hantraye P, Aebischer P, Kordower JH. Related Articles, l

Lentivirally delivered glial cell line-derived neurotroph factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration
J Neurosci. 2002 Jun 15;22(12):4942-54.
PMID: 12077191 [PubMed - indexed for MEDLINE]

☐ **19:** Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Mallol J, Canela EI, Zoli M, Agnati LF, Ibanez CF, Lluis C, Franco R, Ferre S, Fuxe K. Related Articles, l

Coaggregation, cointernalization, and codesensitization adenosine A2A receptors and dopamine D2 receptors.
J Biol Chem. 2002 May 17;277(20):18091-7. Epub 2002 Feb 2
PMID: 11872740 [PubMed - indexed for MEDLINE]

☐ **20:** Jones IW, Bolam JP, Wonnacott S. Related Articles, l

Presynaptic localisation of the nicotinic acetylcholine receptor beta2 subunit immunoreactivity in rat nigrostri dopaminergic neurones.
J Comp Neurol. 2001 Oct 15;439(2):235-47.
PMID: 11596051 [PubMed - indexed for MEDLINE]

☐ **21:** Pierantozzi M, Pietroiusti A, Sancesario G, Lunardi G, Fedele E, Giacomini P, Frasca S, Galante A, Marciani MG, Stanzione P. Related Articles, l

Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients.
Neurol Sci. 2001 Feb;22(1):89-91.
PMID: 11487216 [PubMed - indexed for MEDLINE]

☐ **22:** Brevig T, Meyer M, Kristensen T, Zimmer J, Holgersson J. Related Articles, I

Xenotransplantation for brain repair: reduction of porci donor tissue immunogenicity by treatment with anti-Ga antibodies and complement.
Transplantation. 2001 Jul 27;72(2):190-6.
PMID: 11477337 [PubMed - indexed for MEDLINE]

☐ **23:** Hartmann A, Michel PP, Troadec JD, Mouatt-Prigent A, Faucheux BA, Ruberg M, Agid Y, Hirsch EC. Related Articles, I

Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
J Neurochem. 2001 Mar;76(6):1785-93.
PMID: 11259496 [PubMed - indexed for MEDLINE]

☐ **24:** Choi P, Ostrerova-Golts N, Sparkman D, Cochran E, Lee JM, Wolozin B. Related Articles, I

Parkin is metabolized by the ubiquitin/proteosome syste
Neuroreport. 2000 Aug 21;11(12):2635-8.
PMID: 10976934 [PubMed - indexed for MEDLINE]

☐ **25:** Larsson LC, Widner H. Related Articles, I

Neural tissue xenografting.
Scand J Immunol. 2000 Sep;52(3):249-56. Review.
PMID: 10972900 [PubMed - indexed for MEDLINE]

☐ **26:** Perez M, Lim F, Arrasate M, Avila J. Related Articles, I

The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules.
J Neurochem. 2000 Jun;74(6):2583-9.
PMID: 10820221 [PubMed - indexed for MEDLINE]

☐ **27:** Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, Fischman AJ, Thomas C, Feldman RG, Kassissieh S, Raineri R, Manhart C, Penney D, Fink JS, Isacson O. Related Articles, I

Transplantation of embryonic porcine mesencephalic tissue in patients with PD.
Neurology. 2000 Mar 14;54(5):1042-50.
PMID: 10720272 [PubMed - indexed for MEDLINE]

☐ **28:** Sumitran S, Anderson P, Widner H, Holgersson J. Related Articles, l

Porcine embryonic brain cell cytotoxicity mediated by human natural killer cells.
Cell Transplant. 1999 Nov-Dec;8(6):601-10.
PMID: 10701489 [PubMed - indexed for MEDLINE]

☐ **29:** Deglon N, Tseng JL, Bensadoun JC, Zurn AD, Arsenijevic Y, Pereira de Almeida L, Zufferey R, Trono D, Aebischer P. Related Articles, l

Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system i Parkinson's disease.
Hum Gene Ther. 2000 Jan 1;11(1):179-90.
PMID: 10646649 [PubMed - indexed for MEDLINE]

☐ **30:** Hashimoto S, Sawada T, Inoue T, Yamamoto K, Iwata M. Related Articles, l

Cholinergic-drug induced sicca syndrome in Parkinson' disease: a case report and a review of the literature.
Clin Neurol Neurosurg. 1999 Dec;101(4):268-70. Review.
PMID: 10622459 [PubMed - indexed for MEDLINE]

☐ **31:** Hulette CM, Pericak-Vance MA, Roses AD, Schmechel DE, Yamaoka LH, Gaskell PC, Welsh-Bohmer KA, Crowther RA, Spillantini MG. Related Articles, l

Neuropathological features of frontotemporal dementia and parkinsonism linked to chromosome 17q21-22 (FT 17): Duke Family 1684.
J Neuropathol Exp Neurol. 1999 Aug;58(8):859-66.
PMID: 10446810 [PubMed - indexed for MEDLINE]

☐ **32:** Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Sisk A, Masliah E. Related Articles, l

Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein Lewy body disease as revealed by proteinase K and for acid pretreatment.
Lab Invest. 1998 Sep;78(9):1169-77.
PMID: 9759660 [PubMed - indexed for MEDLINE]

Walker DG, Beach TG, Xu R, Lile J, Beck

☐ **33:** KD, McGeer EG, McGeer PL. Related Articles, l

Expression of the proto-oncogene Ret, a component of GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease.
Brain Res. 1998 May 11;792(2):207-17.
PMID: 9593897 [PubMed - indexed for MEDLINE]

☐ **34:** Kroll RA, Neuwelt EA. Related Articles, l

Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means.
Neurosurgery. 1998 May;42(5):1083-99; discussion 1099-100. Review.
PMID: 9588554 [PubMed - indexed for MEDLINE]

☐ **35:** Fink JS. Related Articles, l

Transplantation in Parkinson's disease.
Artif Organs. 1997 Nov;21(11):1199-202. Review.
PMID: 9384326 [PubMed - indexed for MEDLINE]

☐ **36:** Kordower JH, Styren S, Clarke M, DeKosky ST, Olanow CW, Freeman TB. Related Articles, l

Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants.
Cell Transplant. 1997 May-Jun;6(3):213-9.
PMID: 9171154 [PubMed - indexed for MEDLINE]

☐ **37:** Zlokovic BV, Apuzzo ML. Related Articles, l

Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous syste
Neurosurgery. 1997 Apr;40(4):789-803; discussion 803-4. Revi
PMID: 9092853 [PubMed - indexed for MEDLINE]

☐ **38:** Borlongan CV, Stahl CE, Cameron DF, Saporta S, Freeman TB, Cahill DW, Sanberg PR. Related Articles, l

CNS immunological modulation of neural graft rejectio and survival.
Neurol Res. 1996 Aug;18(4):297-304. Review.
PMID: 8875445 [PubMed - indexed for MEDLINE]

☐ **39:** Schneider JS, Roeltgen DP, Rothblat DS, Chapas-Crilly J, Seraydarian L, Rao J. Related Articles, l

GM1 ganglioside treatment of Parkinson's disease: an o pilot study of safety and efficacy.
Neurology. 1995 Jun;45(6):1149-54.
PMID: 7783880 [PubMed - indexed for MEDLINE]

☐ **40:** Ansari AA, Mayne A, Freed CR, Breeze RE, Schneck SA, O'Brien CF, Kriek EH, Zhang YB, Mazziotta JC, Hutchinson M, et al. Related Articles, l

Lack of a detectable systemic humoral/cellular allogene response in human and nonhuman primate recipients of embryonic mesencephalic allografts for the therapy of Parkinson's disease.
Transplant Proc. 1995 Feb;27(1):1401-5. No abstract available.
PMID: 7878926 [PubMed - indexed for MEDLINE]

☐ **41:** Lorigados L, Molina H, Serrano T, Pavon N, Robinson MA, Alvarez L, Soderstrom S, Ebendal T. Related Articles, l

Evolutive levels of NGF in neurodegenerative disorders
Mol Chem Neuropathol. 1995 Feb-Apr;24(2-3):231-4. No abstı available.
PMID: 7632325 [PubMed - indexed for MEDLINE]

☐ **42:** Nakao N, Itakura T, Uematsu Y, Nakai M, Komai N, Furukawa S. Related Articles, l

Pretreatment with interleukin-1 enhances survival of sympathetic ganglionic neuron grafts.
Neurol Med Chir (Tokyo). 1994 Jul;34(7):407-11.
PMID: 7526227 [PubMed - indexed for MEDLINE]

☐ **43:** Masaki T, Ishiura S, Sugita H, Kwak S. Related Articles, l

Multicatalytic proteinase is associated with characterist oval structures in cortical Lewy bodies: an immunocytochemical study with light and electron microscopy.
J Neurol Sci. 1994 Apr;122(2):127-34.
PMID: 8021694 [PubMed - indexed for MEDLINE]

☐ **44:** Kryzhanovskii GN, Man'kovskii NB, Karaban' IN, Magaeva SV, Trekova NA, Vetrile LA, Basharova LA, Atadzhanov MA, Related Articles, l

Golubev KM.

[Serotonin antibodies and their possible role in parkinsonism]
Zh Nevropatol Psikhiatr Im S S Korsakova. 1994;94(5):21-6. Russian.
PMID: 7900444 [PubMed - indexed for MEDLINE]

☐ **45:** Visser LH, Koudstaal PJ, van de Merwe JP. Related Articles, l

Hemiparkinsonism in a patient with primary Sjogren's syndrome. A case report and a review of the literature.
Clin Neurol Neurosurg. 1993 Jun;95(2):141-5.
PMID: 8344013 [PubMed - indexed for MEDLINE]

☐ **46:** Nagao T, Takagi K, Hashida H, Masaki T, Sakuta M. Related Articles, l

[A case of progressive systemic sclerosis and Sjogren's syndrome complicated by parkinsonism with special reference to the beneficial effect of corticosteroid]
Rinsho Shinkeigaku. 1991 Nov;31(11):1238-40. Japanese.
PMID: 1813195 [PubMed - indexed for MEDLINE]

☐ **47:** Fiszer U, Piotrowska K, Korlak J, Czlonkowska A. Related Articles, l

The immunological status in Parkinson's disease.
Med Lab Sci. 1991 Jul;48(3):196-200.
PMID: 1787777 [PubMed - indexed for MEDLINE]

☐ **48:** Carvey PM, McRae A, Lint TF, Ptak LR, Lo ES, Goetz CG, Klawans HL. Related Articles, l

The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic marke in Parkinson's disease.
Neurology. 1991 May;41(5 Suppl 2):53-8; discussion 59-60. Review.
PMID: 2041594 [PubMed - indexed for MEDLINE]

☐ **49:** Rahamim E, Kahane A, Sharon R. Related Articles, l

Electron microscopy of red blood cells altered by auto-immunity-inducing drugs.
Vox Sang. 1990;58(4):292-9.
PMID: 2399695 [PubMed - indexed for MEDLINE]

Carvey PM, McRae A, Ptak LR, Kao LC, Lo

☐ **50:** ES, Goetz CG, Tanner CM, Penn RD, Klawans HL. Related Articles, l

Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship striatal-derived DA neuron trophic factor.
Prog Brain Res. 1990;82:693-7. No abstract available.
PMID: 2290972 [PubMed - indexed for MEDLINE]

☐ **51:** Ahlskog JE, Tyce GM, Kelly PJ, van Heerden JA, Stoddard SL, Carmichael SW. Related Articles, l

Cerebrospinal fluid indices of blood-brain barrier permeability following adrenal-brain transplantation in patients with Parkinson's disease.
Exp Neurol. 1989 Aug;105(2):152-61.
PMID: 2753115 [PubMed - indexed for MEDLINE]

☐ **52:** Uchida K, Kohsaka S. Related Articles, l

[Current advances in neural transplantation]
Hum Cell. 1989 Jun;2(2):150-5. Japanese.
PMID: 2577249 [PubMed - indexed for MEDLINE]

☐ **53:** McRae-Degueurce A, Klawans HL, Penn RD, Dahlstrom A, Tanner CM, Goetz CG, Carvey PM. Related Articles, l

An antibody in the CSF of Parkinson's disease patients disappears following adrenal medulla transplantation.
Neurosci Lett. 1988 Nov 22;94(1-2):192-7.
PMID: 3241668 [PubMed - indexed for MEDLINE]

☐ **54:** Schmidt ML, Gur RE, Gur RC, Trojanowski JQ. Related Articles, l

Intraneuronal and extracellular neurofibrillary tangles exhibit mutually exclusive cytoskeletal antigens.
Ann Neurol. 1988 Feb;23(2):184-9.
PMID: 3377439 [PubMed - indexed for MEDLINE]

☐ **55:** Brundin P, Strecker RE, Widner H, Clarke DJ, Nilsson OG, Astedt B, Lindvall O, Bjorklund A. Related Articles, l

Human fetal dopamine neurons grafted in a rat model o Parkinson's disease: immunological aspects, spontaneo and drug-induced behaviour, and dopamine release.

Exp Brain Res. 1988;70(1):192-208.
PMID: 3402564 [PubMed - indexed for MEDLINE]

☐ **56:** Ueno S, Takahashi M, Kajiyama K, Okahisa N, Hazama T, Yorifuji S, Tarui S. Related Articles, l

Parkinson's disease and myasthenia gravis: adverse effe of trihexyphenidyl on neuromuscular transmission.
Neurology. 1987 May;37(5):832-3.
PMID: 3033545 [PubMed - indexed for MEDLINE]

☐ **57:** Riederer P, Konradi C, Schay V, Kienzl E, Birkmayer G, Danielczyk W, Sofic E, Youdim MB. Related Articles, l

Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprer
Adv Neurol. 1987;45:111-8.
PMID: 3030067 [PubMed - indexed for MEDLINE]

☐ **58:** Brundin P, Nilsson OG, Strecker RE, Lindvall O, Astedt B, Bjorklund A. Related Articles, l

Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease.
Exp Brain Res. 1986;65(1):235-40.
PMID: 3542544 [PubMed - indexed for MEDLINE]

☐ **59:** Pletscher A. Related Articles, l

[Research--the source of medical progress]
Hautarzt. 1985;36 Suppl 7:1-5. German. No abstract available.
PMID: 3842698 [PubMed - indexed for MEDLINE]

☐ **60:** Pouplard A, Emile J. Related Articles, l

Autoimmunity in Parkinson's disease.
Adv Neurol. 1984;40:307-13. No abstract available.
PMID: 6695608 [PubMed - indexed for MEDLINE]

☐ **61:** Marttila RJ, Rinne UK. Related Articles, l

Epidemiology of Parkinson's disease--an overview.
J Neural Transm. 1981;51(1-2):135-48.
PMID: 7264626 [PubMed - indexed for MEDLINE]

☐ **62:** Marais C. Related Articles, l

[Duality of dopaminergic receptors. Pharmacologic and clinical perspectives]

Sem Hop. 1978 May;54(13-16):563-7. Review. French.
PMID: 211603 [PubMed - indexed for MEDLINE]

☐ **63:** Gyorkey F, Cabral GA, Gyorkey PK, Uribe-Botero G, Dreesman GR, Melnick JL. Related Articles, l

Coxsackievirus aggregates in muscle cells of a polymyositis patient.
Intervirology. 1978;10(2):69-77.
PMID: 352989 [PubMed - indexed for MEDLINE]

☐ **64:** Linstrom FD, Lieden G, Enstrom MS. Related Articles, l

Dose-related levodopa-induced haemolytic anaemia.
Ann Intern Med. 1977 Mar;86(3):298-300.
PMID: 402877 [PubMed - indexed for MEDLINE]

☐ **65:** Territo MC, Peters RW, Tanaka KR. Related Articles, l

Autoimmune hemolytic anemia due to levodopa therap
JAMA. 1973 Dec 10;226(11):1347-8. No abstract available.
PMID: 4202390 [PubMed - indexed for MEDLINE]

☐ **66:** Goldberg LS, Bluestone R. Related Articles, l

Studies on serologic abnormalities induced by L-dopa.
Vox Sang. 1973 Feb;24(2):171-4. No abstract available.
PMID: 4539455 [PubMed - indexed for MEDLINE]

☐ **67:** Boyd AE 3rd, Lebovitz HE, Feldman JM. Related Articles, l

Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-Dop
J Clin Endocrinol Metab. 1971 Nov;33(5):829-37. No abstract available.
PMID: 5125386 [PubMed - indexed for MEDLINE]

☐ **68:** Henry RE, Goldberg LS, Sturgeon P, Ansel RD. Related Articles, l

Serologic abnormalities associated with L-dopa therapy
Vox Sang. 1971 Apr;20(4):306-16. No abstract available.
PMID: 4999317 [PubMed - indexed for MEDLINE]

☐ **69:** Nagay B. Related Articles, l

[Dupuytren's contracture]
Wiad Lek. 1970 Nov 15;23(22):1979-83. Review. Polish. No abstract available.
PMID: 4922139 [PubMed - indexed for MEDLINE]

☐ **70:** Cotzias GC, Papavasiliou PS. Related Articles, l

Autoimmunity in patients treated with levodopa.
JAMA. 1969 Feb 17;207(7):1353-4. No abstract available.
PMID: 5304532 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Mar 14 2005 07:08:36

```
Connecting via Winsock to STN
Welcome to STN International!  Enter x:x
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  SEP 01  New pricing for the Save Answers for SciFinder Wizard within
                  STN Express with Discover!
 NEWS  4  OCT 28  KOREAPAT now available on STN
 NEWS  5  NOV 30  PHAR reloaded with additional data
 NEWS  6  DEC 01  LISA now available on STN
 NEWS  7  DEC 09  12 databases to be removed from STN on December 31, 2004
 NEWS  8  DEC 15  MEDLINE update schedule for December 2004
 NEWS  9  DEC 17  ELCOM reloaded; updating to resume; current-awareness
                  alerts (SDIs) affected
 NEWS  10 DEC 17  COMPUAB reloaded; updating to resume; current-awareness
                  alerts (SDIs) affected
 NEWS  11 DEC 17  SOLIDSTATE reloaded; updating to resume; current-awareness
                  alerts (SDIs) affected
 NEWS  12 DEC 17  CERAB reloaded; updating to resume; current-awareness
                  alerts (SDIs) affected
 NEWS  13 DEC 17  THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
 NEWS  14 DEC 30  EPFULL: New patent full text database to be available on STN
 NEWS  15 DEC 30  CAPLUS - PATENT COVERAGE EXPANDED
 NEWS  16 JAN 03  No connect-hour charges in EPFULL during January and
                  February 2005
 NEWS  17 FEB 25  CA/CAPLUS - Russian Agency for Patents and Trademarks
                  (ROSPATENT) added to list of core patent offices covered
 NEWS  18 FEB 10  STN Patent Forums to be held in March 2005
 NEWS  19 FEB 16  STN User Update to be held in conjunction with the 229th ACS
                  National Meeting on March 13, 2005
 NEWS  20 FEB 28  PATDPAFULL - New display fields provide for legal status
                  data from INPADOC
 NEWS  21 FEB 28  BABS - Current-awareness alerts (SDIs) available
 NEWS  22 FEB 28  MEDLINE/LMEDLINE reloaded
 NEWS  23 MAR 02  GBFULL: New full-text patent database on STN
 NEWS  24 MAR 03  REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  25 MAR 03  MEDLINE file segment of TOXCENTER reloaded
 NEWS  26 MAR 22  KOREAPAT now updated monthly; patent information enhanced
 NEWS  27 MAR 22  Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  28 MAR 22  PATDPASPC - New patent database available
 NEWS  29 MAR 22  REGISTRY/ZREGISTRY enhanced with experimental property tags

 NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:22:22 ON 22 MAR 2005

=> file BIOSCIENCE
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ADISCTI' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 17:22:31 ON 22 MAR 2005
```

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 17:22:31 ON 22 MAR 2005

FILE 'ANABSTR' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (c) 2005 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT 2005 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 17:22:31 ON 22 MAR 2005
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 17:22:31 ON 22 MAR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 17:22:31 ON 22 MAR 2005

FILE 'CAPLUS' ENTERED AT 17:22:31 ON 22 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (c) 2005 DECHEMA eV

FILE 'CEN' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 17:22:31 ON 22 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 17:22:31 ON 22 MAR 2005

FILE 'FOMAD' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 International Food Information Service

FILE 'GENBANK' ENTERED AT 17:22:31 ON 22 MAR 2005

FILE 'HEALSAFE' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (c) 2005 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 17:22:31 ON 22 MAR 2005

FILE 'NIOSHTIC' ENTERED AT 17:22:31 ON 22 MAR 2005

COPYRIGHT (C) 2005 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 17:22:31 ON 22 MAR 2005
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2005)

FILE 'NUTRACEUT' ENTERED AT 17:22:31 ON 22 MAR 2005
Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 17:22:31 ON 22 MAR 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 WIPO

FILE 'PHAR' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PHARMAML' ENTERED AT 17:22:31 ON 22 MAR 2005
Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PHIN' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PROMT' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'PS' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 17:22:31 ON 22 MAR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'SYNTHLINE' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'TOXCENTER' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 17:22:31 ON 22 MAR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:22:31 ON 22 MAR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

```
FILE 'WPIFV' ENTERED AT 17:22:31 ON 22 MAR 2005
COPYRIGHT (C) 2005 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S Lewy body OR alpha-synuclein
  23 FILES SEARCHED...
  36 FILES SEARCHED...
  58 FILES SEARCHED...
  71 FILES SEARCHED...
L1        31933 LEWY BODY OR ALPHA-SYNUCLEIN

=> S L1 Abeta
MISSING OPERATOR L1 ABETA
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> S L1 AND abeta
  29 FILES SEARCHED...
  62 FILES SEARCHED...
L2         1623 L1 AND ABETA

=> DUP REM L2
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, PS, RDISCLOSURE,
SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L2
L3          1466 DUP REM L2 (157 DUPLICATES REMOVED)

=> S L3 AND immunization
  15 FILES SEARCHED...
  32 FILES SEARCHED...
  47 FILES SEARCHED...
  62 FILES SEARCHED...
L4           21 L3 AND IMMUNIZATION

=> D L4 1-21

L4   ANSWER 1 OF 21  BIOSIS  COPYRIGHT (c) 2005 The Thomson Corporation  on STN
AN   2004:355388  BIOSIS
DN   PREV200400362351
TI   Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking
     of B cell tolerance by virus-like particles in amyloidbeta immunized
     amyloid precursor protein transgenic mice.
AU   Li, Qingyou; Cao, Chuanhai; Chackerian, Bryce; Schiller, John; Gordon,
     Marcia; Ugen, Kenneth E.; Morgan, Dave [Reprint Author]
CS   Dept PharmacolAlzheimers Res Lab, Univ S Florida, Tampa, FL, 33612, USA
     qli@hsc.usf.edu; ccao@hsc.usf.edu; brycec@nih.gov;
     schillej@dc37a.nci.nih.gov; mgordon@hsc.usf.edu; kugen@hsc.usf.edu;
     dmorgan@hsc.usf.edu
SO   BMC Neuroscience, (June 8 2004) Vol. 5, No. June 8. print.
     ISSN: 1471-2202 (ISSN online).
DT   Article
LA   English
ED   Entered STN: 5 Sep 2004
     Last Updated on STN: 5 Sep 2004

L4    ANSWER 2 OF 21  BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
AN    2002-13062  BIOTECHDS
TI    Composition comprising fusion protein which comprises binding portion
      that binds amyloid peptide epitope and a segment crossing blood-brain
      barrier, useful for treating disease states associated with amyloidosis;
         recombinant protein gene production, fusion protein composition,
         vector expression in host cell, useful in disease therapy and
         diagnosis
AU    NICOLAU Y C
PA    AVENTIS PHARMA SA; UNIV PASTEUR LOUIS
PI    WO 2002021141 14 Mar 2002
AI    WO 2000-US27632 6 Sep 2000
```

PRAI US 2000-255033 12 Dec 2000
DT Patent
LA English
OS WPI: 2002-351803 [38]

L4 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:412731 CAPLUS
DN 140:417964
TI Prevention and treatment of synucleinopathic disease by administering agents that induce a beneficial immunogenic response against ***Lewy*** ***bodies***
IN Schenk, Dale B.; Masliah, Eliezer
PA Elan Pharmaceuticals, Inc., USA; The Regents of the University of California
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004041067	A2	20040521	WO 2003-US34527	20031031

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-423012P P 20021101

L4 ANSWER 4 OF 21 IFIPAT COPYRIGHT 2005 IFI on STN
AN 10243450 IFIPAT;IFIUDB;IFICDB
TI NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID; ADMINISTERING AN AMYLOIDOGENIC POLYPEPTIDE OR SUBSEQUENCE THEREOF TO INDUCES PRODUCTION OF ANTIBODIES AGAINST THE AMYLOIDOGENIC POLYPEPTIDE; TREATMENT OF ALZHEIMER'S DISEASE
IN Jensen Martin Roland (DK); Nielsen Klaus Gregorius (DK); Rasmussen Peter Birk (DK)
PA Unassigned Or Assigned To Individual (68000)
PI US 2002187157 A1 20021212
AI US 2001-785215 20010220
PRAI PA 2000-265 20000221
US 2000-186295P 20000301 (Provisional)
FI US 2002187157 20021212
DT Utility; Patent Application - First Publication **
00001000
FS CHEMICAL
APPLICATION
CLMN 58
GI 1 Figure(s).
FIG. 1: Schematic depiction of Autovac variants derived from the amyloid precursor protein with the purpose of generating antibody responses against the A beta protein A beta-43 (or C100). The APP is shown schematically at the top of the figure and the remaining schematic constructs show that the model epitopes P2 and P30 are substituted or inserted into various truncations of APP. In the figure, the black pattern indicates the APP signal sequence, two-way cross-hatching is the extracellular part of APP, dark vertical hatching is the transmembrane domain of APP, light vertical hatching is the intracellular domain of APP, coarse cross-hatching indicates the P30 epitope, and fine cross-hatching indicates the P2 epitope. The full line box indicates A beta-42/43 and the fullline box and the dotted line box together indicate C-100. " ***Abeta*** " denotes A beta .

L4 ANSWER 5 OF 21 USPATFULL on STN
AN 2005:36976 USPATFULL
TI Therapeutic formulations for the treatment of beta-amyloid related diseases

IN Gervais, Francine, Ile Bizard, CANADA
Bellini, Francesco, Mount Royal, CANADA
PI US 2005031651 A1 20050210
AI US 2004-871537 A1 20040618 (10)
RLI Continuation-in-part of Ser. No. US 2003-746138, filed on 24 Dec 2003, PENDING
PRAI WO 2003-CA2011 20031224
US 2002-436379P 20021224 (60)
US 2003-482214P 20030623 (60)
US 2003-480984P 20030623 (60)
US 2003-512116P 20031017 (60)
US 2003-482058P 20030623 (60)
US 2003-512135P 20031017 (60)
US 2003-480918P 20030623 (60)
US 2003-512017P 20031017 (60)
US 2003-480906P 20030623 (60)
US 2003-512047P 20031017 (60)
DT Utility
FS APPLICATION
LN.CNT 7983
INCL INCLM: 424/400.000
NCL NCLM: 424/400.000
IC [7]
ICM: A61K009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 21 USPATFULL on STN
AN 2005:10897 USPATFULL
TI Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
IN Becker, Kenneth David, San Diego, CA, UNITED STATES
Velicelebi, Gonul, San Diego, CA, UNITED STATES
Elliott, Kathryn J., San Diego, CA, UNITED STATES
Wang, Xin, San Diego, CA, UNITED STATES
Tanzi, Rudolph E., Hull, MA, UNITED STATES
Bertram, Lars, Boston, MA, UNITED STATES
Saunders, Aleister J., Philadelphia, PA, UNITED STATES
Mullin, Kristina M., Weymouth, MA, UNITED STATES
Sampson, Andrew Joseph, Oakwood, OH, UNITED STATES
PI US 2005009031 A1 20050113
AI US 2003-600009 A1 20030618 (10)
RLI Continuation-in-part of Ser. No. US 2002-282174, filed on 25 Oct 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US34679, filed on 25 Oct 2002, PENDING
PRAI US 2001-339525P 20011025 (60)
US 2001-338010P 20011108 (60)
US 2001-336929P 20011108 (60)
US 2001-338363P 20011109 (60)
US 2001-337052P 20011204 (60)
US 2002-368919P 20020328 (60)
DT Utility
FS APPLICATION
LN.CNT 15528
INCL INCLM: 435/006.000
INCLS: 536/024.300
NCL NCLM: 435/006.000
NCLS: 536/024.300
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 21 USPATFULL on STN
AN 2004:334837 USPATFULL
TI Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
IN Vanderstichele, Hugo, Gent, BELGIUM
Vanmechelen, Eugeen, Nażareth-Eke, BELGIUM
De Meyer, Geert, Gent, BELGIUM
Blennow, Kaj, Goteborg, SWEDEN
Kostanjevecki, Vesna, Sint-Denijs-Westrem, BELGIUM
PI US 2004265919 A1 20041230

AI US 2004-848686 A1 20040519 (10)
PRAI EP 2003-447120 20030522
US 2003-477621P 20030611 (60)
DT Utility
FS APPLICATION
LN.CNT 2860
INCL INCLM: 435/007.200
NCL NCLM: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 21 USPATFULL on STN
AN 2004:327335 USPATFULL
TI Methods of engineering spatially conserved motifs in polypeptides
IN Chan, John, Raleigh, NC, UNITED STATES
Zhang, Shengsheng, Framingham, MA, UNITED STATES
Baynes, Brian, Somerville, MA, UNITED STATES
PA Compound Therapeutics, Inc., Waltham, MA (U.S. corporation)
PI US 2004259155 A1 20041223
AI US 2003-676873 A1 20030930 (10)
PRAI US 2002-414688P 20020930 (60)
DT Utility
FS APPLICATION
LN.CNT 2745
INCL INCLM: 435/007.100
INCLS: 702/019.000
NCL NCLM: 435/007.100
NCLS: 702/019.000
IC [7]
ICM: G01N033-53
ICS: G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 21 USPATFULL on STN
AN 2004:120535 USPATFULL
TI Peptides and methods of screening immunogenic peptide vaccines against Alzheimer's Disease
IN Fitzer-Attas, Cheryl, Rehovot, ISRAEL
Chain, Daniel G., Jerusalem, ISRAEL
PI US 2004091945 A1 20040513
AI US 2003-619454 A1 20030716 (10)
PRAI US 2002-396245P 20020717 (60)
DT Utility
FS APPLICATION
LN.CNT 2604
INCL INCLM: 435/007.200
INCLS: 530/350.000
NCL NCLM: 435/007.200
NCLS: 530/350.000
IC [7]
ICM: G01N033-53
ICS: G01N033-567; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 21 USPATFULL on STN
AN 2004:107249 USPATFULL
TI Adzymes and uses thereof
IN Afeyan, Noubar B., Lexington, MA, UNITED STATES
Lee, Frank D., Chestnut Hill, MA, UNITED STATES
Wong, Gordon G., Brookline, MA, UNITED STATES
Das Gupta, Ruchira, Auburndale, MA, UNITED STATES
Baynes, Brian, Somerville, MA, UNITED STATES
PI US 2004081648 A1 20040429
AI US 2003-650592 A1 20030827 (10)
PRAI US 2002-406517P 20020827 (60)
US 2002-423754P 20021105 (60)
US 2002-430001P 20021127 (60)
DT Utility
FS APPLICATION
LN.CNT 8325

INCL INCLM: 424/094.630
INCLS: 435/226.000
NCL NCLM: 424/094.630
NCLS: 435/226.000
IC [7]
ICM: A61K038-48
ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 21 USPATFULL on STN
AN 2004:107248 USPATFULL
TI Adzymes and uses thereof
IN Afeyan, Noubar B., Lexington, MA, UNITED STATES
Lee, Frank D., Chestnut Hill, MA, UNITED STATES
Wong, Gordon G., Brookline, MA, UNITED STATES
DàsGupta, Ruchira, Auburndale, MA, UNITED STATES
Baynes, Brian, Somerville, MA, UNITED STATES
PI US 2004081647 A1 20040429
AI US 2003-650591 A1 20030827 (10)
PRAI US 2002-406517P 20020827 (60)
US 2002-423754P 20021105 (60)
US 2002-430001P 20021127 (60)
DT Utility
FS APPLICATION
LN.CNT 7919
INCL INCLM: 424/094.630
INCLS: 435/069.700; 435/226.000
NCL NCLM: 424/094.630
NCLS: 435/069.700; 435/226.000
IC [7]
ICM: A61K038-48
ICS: C12N009-64; C12P021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 21 USPATFULL on STN
AN 2004:51633 USPATFULL
TI Amine 1,2- and 1,3-diol compounds
IN Romero, Arthur G., Kalamazoo, MI, UNITED STATES
Schostarez, Heinrich J., Portage, MI, UNITED STATES
Roels, Christina M., Battle Creek, MI, UNITED STATES
PI US 2004039064 A1 20040226
AI US 2002-299739 A1 20021119 (10)
PRAI US 2001-333081P 20011119 (60)
US 2001-334000P 20011128 (60)
US 2002-362752P 20020308 (60)
DT Utility
FS APPLICATION
LN.CNT 10130
INCL INCLM: 514/651.000
INCLS: 564/355.000
NCL NCLM: 514/651.000
NCLS: 564/355.000
IC [7]
ICM: A61K031-137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 21 USPATFULL on STN
AN 2004:44501 USPATFULL
TI Proteins and nucleic acids encoding same
IN Tchernev, Velizar T., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shimkets, Richard A., West Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Miller, Charles E., Hill Drive, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES

Gusev, Vladimir Y., UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Wolenc, Adam Ryan, New Haven, CT, UNITED STATES
Pena, Carol E. A., Guilford, CT, UNITED STATES
Furtak, Katarzyna, Anosia, CT, UNITED STATES
Grosse, William M., Bransford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Rieger, Daniel K., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
PI US 2004033493 A1 20040219
AI US 2002-72012 A1 20020131 (10)
PRAI US 2001-267459P 20010208 (60)
US 2001-266975P 20010207 (60)
US 2001-267057P 20010207 (60)
US 2001-266767P 20010205 (60)
US 2001-266406P 20010202 (60)
US 2001-265395P 20010131 (60)
US 2001-265412P 20010131 (60)
US 2001-265517P 20010131 (60)
US 2001-265514P 20010131 (60)
US 2001-267823P 20010209 (60)
US 2001-268974P 20010215 (60)
US 2001-271855P 20010227 (60)
US 2001-271839P 20010227 (60)
US 2001-273046P 20010302 (60)
US 2001-272788P 20010302 (60)
US 2001-275989P 20010314 (60)
US 2001-275925P 20010314 (60)
US 2001-275947P 20010314 (60)
US 2001-275950P 20010314 (60)
US 2001-276450P 20010315 (60)
US 2001-276448P 20010315 (60)
US 2001-276397P 20010316 (60)
US 2001-276768P 20010316 (60)
US 2001-278652P 20010320 (60)
US 2001-278775P 20010326 (60)
US 2001-278778P 20010326 (60)
US 2001-279882P 20010329 (60)
US 2001-279884P 20010329 (60)
US 2001-280147P 20010330 (60)
US 2001-283083P 20010411 (60)
US 2001-282992P 20010411 (60)
US 2001-285133P 20010420 (60)
US 2001-285749P 20010423 (60)
US 2001-288327P 20010503 (60)
US 2001-288504P 20010503 (60)
US 2001-294047P 20010529 (60)
US 2001-294473P 20010530 (60)
US 2001-296964P 20010608 (60)
US 2001-298959P 20010618 (60)
US 2001-299324P 20010619 (60)
US 2001-312020P 20010813 (60)
US 2001-312908P 20010816 (60)
US 2001-312889P 20010816 (60)
US 2001-313930P 20010821 (60)
US 2001-315470P 20010828 (60)
US 2001-316447P 20010831 (60)
US 2001-318115P 20010907 (60)
US 2001-318118P 20010907 (60)
US 2001-318740P 20010912 (60)
US 2001-323379P 20010919 (60)
US 2001-330308P 20011018 (60)
US 2001-330245P 20011018 (60)
US 2001-332701P 20011114 (60)
US 2001-271664P 20010226 (60)
DT Utility
FS APPLICATION
LN.CNT 59681
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.300; 435/320.100; 435/325.000; 530/350.000;
536/023.200; 435/183.000; 424/155.100

NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 435/183.000; 424/155.100
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; A61K039-395; C12N009-00; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 21 USPATFULL on STN
AN 2004:18378 USPATFULL
TI Neurotoxic oligomers
IN Bush, Ashley, Somerville, MA, UNITED STATES
Cherny, Robert, Victoria, AUSTRALIA
PI US 2004013680 A1 20040122
AI US 2003-312437 A1 20030616 (10)
WO 2001-AU786 20010628
DT Utility
FS APPLICATION
LN.CNT 1214
INCL INCLM: 424/185.100
INCLS: 530/400.000
NCL NCLM: 424/185.100
NCLS: 530/400.000
IC [7]
ICM: A61K039-00
ICS: C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 21 USPATFULL on STN
AN 2003:325156 USPATFULL
TI Aza hydroxylated ethyl amine compounds utility
IN Schostarez, Heinrich, Portage, MI, UNITED STATES
Chrusciel, Robert Alan, Portage, MI, UNITED STATES
Centko, Rebecca S., Portage, MI, UNITED STATES
PI US 2003229138 A1 20031211
AI US 2002-152601 A1 20020522 (10)
PRAI US 2001-292856P 20010522 (60)
US 2001-301355P 20010627 (60)
US 2002-360601P 20020301 (60)
DT Utility
FS APPLICATION
LN.CNT 6845
INCL INCLM: 514/526.000
INCLS: 514/664.000; 514/561.000; 514/651.000; 514/614.000; 558/446.000; 562/561.000; 564/147.000; 564/347.000; 564/464.000; 558/445.000
NCL NCLM: 514/526.000
NCLS: 514/664.000; 514/561.000; 514/651.000; 514/614.000; 558/446.000; 562/561.000; 564/147.000; 564/347.000; 564/464.000; 558/445.000
IC [7]
ICM: A61K031-275
ICS: A61K031-195; A61K031-16; A61K031-15; A61K031-137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 21 USPATFULL on STN
AN 2003:318636 USPATFULL
TI Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
IN Becker, Kenneth David, San Diego, CA, UNITED STATES
Velicelebi, Gonul, San Diego, CA, UNITED STATES
Ellliott, Kathryn J., San Diego, CA, UNITED STATES
Wang, Xin, San Diego, CA, UNITED STATES
Tanzi, Rudolph E., Hull, MA, UNITED STATES
Bertram, Lars, Brighton, MA, UNITED STATES
Saunders, Aleister J., Philadelphia, PA, UNITED STATES
Mullin, Kristina M., south Boston, MA, UNITED STATES
Sampson, Andrew Joseph, Dayton, OH, UNITED STATES
PA The General Hospital Corporation (U.S. corporation)
PI US 2003224380 A1 20031204
AI US 2002-282174 A1 20021025 (10)
PRAI US 2001-339525P 20011025 (60)
US 2001-338010P 20011108 (60)

US 2001-336929P 20011108 (60)
US 2001-338363P 20011109 (60)
US 2001-337052P 20011204 (60)
US 2002-368919P 20020328 (60)
US 2001-348065P 20011025 (60)
US 2001-336983P 20011102 (60)
DT Utility
FS APPLICATION
LN.CNT 13662
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 21 USPATFULL on STN
AN 2003:225306 USPATFULL
TI Novel method for down-regulation of amyloid
IN Rasmussen, Peter Birk, Horsholm, DENMARK
Jensen, Martin Roland, Horsholm, DENMARK
Nielsen, Klaus Gregorius, Horsholm, DENMARK
Koefoed, Peter, Horsholm, DENMARK
Degan, Florence Dal, Horsholm, DENMARK
PI US 2003157117 A1 20030821
AI US 2002-223809 A1 20020820 (10)
PRAI DK 2001-1231 20010820
DK 2002-58 20020416
US 2001-337543P 20011022 (60)
US 2002-373027P 20020416 (60)
DT Utility
FS APPLICATION
LN.CNT 3681
INCL INCLM: 424/185.100
INCLS: 435/226.000
NCL NCLM: 424/185.100
NCLS: 435/226.000
IC [7]
ICM: A61K039-00
ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 21 USPATFULL on STN
AN 2003:135733 USPATFULL
TI Transgenic animal model of neurodegenerative disorders
IN St. George-Hyslop, Peter H., Toronto, CANADA
Fraser, Paul E., Toronto, CANADA
Westaway, David, Etobicoke, CANADA
PI US 2003093822 A1 20030515
AI US 2001-884629 A1 20010619 (9)
PRAI US 2000-212534P 20000620 (60)
DT Utility
FS APPLICATION
LN.CNT 1380
INCL INCLM: 800/018.000
INCLS: 800/012.000
NCL NCLM: 800/018.000
NCLS: 800/012.000
IC [7]
ICM: A01K067-027

L4 ANSWER 19 OF 21 USPATFULL on STN
AN 2003:126727 USPATFULL
TI Novel methods for down-regulation of amyloid
IN Jensen, Martin Roland, Horsholm, DENMARK
Birk, Peter, Horsholm, DENMARK
Nielsen, Klaus Gregorius, Horsholm, DENMARK
PI US 2003086938 A1 20030508
AI US 2002-204362 A1 20020816 (10)
WO 2001-DK113 20010219
PRAI DK 2000-265 20000221
DT Utility
FS APPLICATION

LN.CNT 3114
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 21 USPATFULL on STN
AN 2002:191196 USPATFULL
TI Methods and compositions for stimulating CD 45 and thereby suppressing microglial activation associated with Alzheimer's disease
IN Tan, Jun, Tampa, FL, UNITED STATES
Town, Terrence, Tampa, FL, UNITED STATES
Mullan, Michael, Tampa, FL, UNITED STATES
PI US 2002102259 A1 20020801
AI US 2001-985598 A1 20011105 (9)
PRAI US 2000-245608P 20001103 (60)
DT Utility
FS APPLICATION
LN.CNT 1744
INCL INCLM: 424/144.100
NCL NCLM: 424/144.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 21 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2002-130835 [17] WPIDS
DNC C2002-040215
TI Treatment and prevention of conditions characterized by pathological aggregation and accumulation of a specific protein associated with oxidative damage and tyrosine-cross-link formation..
DC B04 D16
IN BUSH, A; CHERNY, R
PA (GEHO) GEN HOSPITAL CORP; (PRAN-N) PRANA BIOTECHNOLOGY LTD; (BUSH-I) BUSH A; (CHER-I) CHERNY R
CYC 97
PI WO 2002000245 A1 20020103 (200217)* EN 59 A61K038-16
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2001068828 A 20020108 (200235) A61K038-16
EP 1296705 A1 20030402 (200325) EN A61K038-16
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
CN 1450908 A 20031022 (200406) A61K038-16
US 2004013680 A1 20040122 (200407) A61K039-00
JP 2004501204 W 20040115 (200410) 96 A61K038-00
ADT WO 2002000245 A1 WO 2001-AU786 20010628; AU 2001068828 A AU 2001-68828 20010628; EP 1296705 A1 EP 2001-947033 20010628, WO 2001-AU786 20010628; CN 1450908 A CN 2001-813312 20010628; US 2004013680 A1 WO 2001-AU786 20010628, US 2003-312437 20030616; JP 2004501204 W WO 2001-AU786 20010628, JP 2002-505026 20010628
FDT AU 2001068828 A Based on WO 2002000245; EP 1296705 A1 Based on WO 2002000245; JP 2004501204 W Based on WO 2002000245
PRAI US 2000-242177P 20001023; US 2000-214779P 20000628; US 2003-312437 20030616
IC ICM A61K038-00; A61K038-16; A61K039-00
ICS A61K039-395; A61P021-00; A61P025-02; A61P025-14; A61P025-16; A61P025-28; A61P027-12; C07K014-47; G01N033-53
STN INTERNATIONAL LOGOFF AT 17:33:43 ON 22 MAR 2005